0000315545 2021-01-01 2021-12-31 0000315545 2021-06-30 0000315545 2022-03-25 0000315545 2021-12-31 0000315545 2020-12-31 0000315545 PVCT:SeriesBConvertiblePreferredStockMember 2021-12-31 0000315545 PVCT:SeriesBConvertiblePreferredStockMember 2020-12-31 0000315545 PVCT:SeriesDConvertiblePreferredStockMember 2021-12-31 0000315545 PVCT:SeriesDConvertiblePreferredStockMember 2020-12-31 0000315545 PVCT:SeriesDOneConvertiblePreferredStockMember 2021-12-31 0000315545 PVCT:SeriesDOneConvertiblePreferredStockMember 2020-12-31 0000315545 2020-01-01 2020-12-31 0000315545 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000315545 PVCT:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000315545 PVCT:SeriesDOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000315545 us-gaap:CommonStockMember 2019-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000315545 us-gaap:RetainedEarningsMember 2019-12-31 0000315545 2019-12-31 0000315545 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000315545 PVCT:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000315545 PVCT:SeriesDOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000315545 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000315545 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000315545 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000315545 PVCT:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000315545 PVCT:SeriesDOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000315545 us-gaap:CommonStockMember 2020-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000315545 us-gaap:RetainedEarningsMember 2020-12-31 0000315545 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000315545 PVCT:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000315545 PVCT:SeriesDOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000315545 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000315545 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000315545 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000315545 PVCT:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000315545 PVCT:SeriesDOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000315545 us-gaap:CommonStockMember 2021-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000315545 us-gaap:RetainedEarningsMember 2021-12-31 0000315545 us-gaap:PatentsMember 2021-12-31 0000315545 us-gaap:PatentsMember 2020-12-31 0000315545 us-gaap:WarrantMember 2021-01-01 2021-12-31 0000315545 us-gaap:WarrantMember 2020-01-01 2020-12-31 0000315545 PVCT:StockOptionsMember 2021-01-01 2021-12-31 0000315545 PVCT:StockOptionsMember 2020-01-01 2020-12-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0000315545 PVCT:TwoThousandSeventeenNoteMember 2019-12-31 0000315545 PVCT:TwoThousandTwentyNoteMember 2019-12-31 0000315545 PVCT:TwoThousandTwentyOneNoteMember 2019-12-31 0000315545 PVCT:TwoThousandSeventeenNoteMember 2020-01-01 2020-12-31 0000315545 PVCT:TwoThousandTwentyNoteMember 2020-01-01 2020-12-31 0000315545 PVCT:TwoThousandTwentyOneNoteMember 2020-01-01 2020-12-31 0000315545 PVCT:TwoThousandSeventeenNoteMember 2020-12-31 0000315545 PVCT:TwoThousandTwentyNoteMember 2020-12-31 0000315545 PVCT:TwoThousandTwentyOneNoteMember 2020-12-31 0000315545 PVCT:TwoThousandSeventeenNoteMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandTwentyNoteMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandTwentyOneNoteMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandSeventeenNoteMember 2021-12-31 0000315545 PVCT:TwoThousandTwentyNoteMember 2021-12-31 0000315545 PVCT:TwoThousandTwentyOneNoteMember 2021-12-31 0000315545 PVCT:TwoThousandTwentyOneNoteMember PVCT:TwoThousandTwentyOneFinancingMember PVCT:ShareBasedCompensationAwardFirstAndFinalTrancheMember 2021-08-13 0000315545 PVCT:InvestorsMember PVCT:TwoThousandTwentyOneNoteMember PVCT:SeriesD1ConvertiblePreferredStockMember 2021-12-31 0000315545 PVCT:InvestorsMember PVCT:TwoThousandTwentyOneNoteMember PVCT:SeriesD1ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandSeventeenNoteMember 2017-03-23 0000315545 PVCT:OfficersMember 2021-12-31 0000315545 PVCT:BoardOfDirectorMember 2021-12-31 0000315545 srt:MinimumMember PVCT:FirmCommitmentMember 2021-12-31 0000315545 PVCT:FirmCommitmentMember 2021-12-31 0000315545 PVCT:TwoThousandSeventeenFinancingMember PVCT:SeriesDAndD1ConvertiblePreferredStockMember 2021-12-31 0000315545 srt:MinimumMember PVCT:TwoThousandSeventeenNotesMember PVCT:SeriesDAndD1ConvertiblePreferredStockMember 2021-12-31 0000315545 srt:MaximumMember PVCT:TwoThousandSeventeenNotesMember PVCT:SeriesDAndD1ConvertiblePreferredStockMember 2021-12-31 0000315545 PVCT:TwoThousandSeventeenFinancingMember PVCT:SeriesDConvertiblePreferredStockMember 2021-12-31 0000315545 PVCT:TwoThousandSeventeenFinancingMember PVCT:SeriesDOneConvertiblePreferredStockMember 2021-12-31 0000315545 PVCT:TwoThousandAndSeventeenNotesMember PVCT:NonAmendedTwoThousandSeventeenFinancingMember 2021-06-20 0000315545 PVCT:TwoThousandAndSeventeenNotesMember PVCT:NonAmendedTwoThousandSeventeenFinancingMember PVCT:SeriesDConvertiblePreferredStockMember 2021-06-19 2021-06-20 0000315545 PVCT:TwoThousandAndSeventeenNotesMember PVCT:NonAmendedTwoThousandSeventeenFinancingMember PVCT:SeriesDConvertiblePreferredStockMember 2021-06-20 0000315545 PVCT:TwoThousandAndSeventeenNotesMember PVCT:AmendedTwoThousandSeventeenFinancingMember 2021-06-20 0000315545 PVCT:TwoThousandAndSeventeenNotesMember PVCT:AmendedTwoThousandSeventeenFinancingMember PVCT:SeriesDOneConvertiblePreferredStockMember 2021-06-19 2021-06-20 0000315545 PVCT:TwoThousandAndSeventeenNotesMember PVCT:AmendedTwoThousandSeventeenFinancingMember PVCT:SeriesDOneConvertiblePreferredStockMember 2021-06-20 0000315545 PVCT:SeriesDConvertiblePreferredStockMember 2021-01-01 2021-12-31 0000315545 PVCT:SeriesDOneConvertiblePreferredStockMember 2021-01-01 2021-12-31 0000315545 PVCT:TheCARESActMember PVCT:PaycheckProtectionProgramMember 2020-04-19 2020-04-20 0000315545 PVCT:TheCARESActMember PVCT:PaycheckProtectionProgramMember 2021-01-01 2021-12-31 0000315545 PVCT:MrBruceHorowitzMember 2021-01-01 2021-12-31 0000315545 PVCT:MrBruceHorowitzMember 2020-01-01 2020-12-31 0000315545 srt:DirectorMember PVCT:MrBruceHorowitzMember 2021-01-01 2021-12-31 0000315545 srt:DirectorMember PVCT:MrBruceHorowitzMember 2020-01-01 2020-12-31 0000315545 PVCT:MrBruceHorowitzMember 2021-12-31 0000315545 PVCT:MrBruceHorowitzMember 2020-12-31 0000315545 srt:DirectorMember PVCT:MrBruceHorowitzMember PVCT:CapitalStrategistMember 2021-01-01 2021-12-31 0000315545 srt:DirectorMember PVCT:MrBruceHorowitzMember PVCT:CapitalStrategistMember 2020-01-01 2020-12-31 0000315545 PVCT:PeterCulpepperMember 2020-12-31 0000315545 us-gaap:SeriesBPreferredStockMember 2016-08-25 0000315545 us-gaap:SeriesBPreferredStockMember 2016-08-24 2016-08-25 0000315545 us-gaap:CommonStockMember 2016-08-25 0000315545 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0000315545 us-gaap:SeriesDPreferredStockMember 2021-12-31 0000315545 PVCT:SeriesDOnePreferredStockMember 2021-12-31 0000315545 us-gaap:SeriesDPreferredStockMember 2021-06-19 2021-06-20 0000315545 us-gaap:SeriesDPreferredStockMember 2021-06-20 0000315545 PVCT:SeriesDOnePreferredStockMember 2021-06-20 0000315545 us-gaap:InvestorMember PVCT:RestrictedSeriesDOnePreferredStockMember 2021-01-01 2021-12-31 0000315545 us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-12-31 0000315545 PVCT:SeriesDOnePreferredStockMember 2021-01-01 2021-12-31 0000315545 PVCT:ContractorOneMember 2020-03-30 2020-04-01 0000315545 PVCT:AdvisoryBoardMemberOneMember 2020-07-30 2020-07-31 0000315545 PVCT:AdvisoryBoardMemberTwoMember 2020-08-30 2020-08-31 0000315545 PVCT:AdvisoryBoardMemberThreeMember 2020-10-25 2020-10-26 0000315545 PVCT:ContractorTwoMember 2020-11-09 2020-11-10 0000315545 PVCT:EmployeeMember 2020-11-09 2020-11-10 0000315545 PVCT:BoardOfDirectorMember 2020-11-09 2020-11-10 0000315545 PVCT:BoardofDirectorOfficerMember 2020-11-09 2020-11-10 0000315545 srt:MaximumMember PVCT:TwoThousandSeventeenEquityCompensationPlanMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandSeventeenEquityCompensationPlanMember 2021-12-31 0000315545 PVCT:OfficerOrDirectorMember PVCT:FiveYearImmediatelyVestedMember 2020-01-01 2020-12-31 0000315545 PVCT:OfficerOrDirectorMember PVCT:FiveYearImmediatelyVestedMember 2020-12-31 0000315545 srt:DirectorMember PVCT:FiveYearImmediatelyVestedMember 2020-01-01 2020-12-31 0000315545 srt:DirectorMember PVCT:FiveYearImmediatelyVestedMember 2020-12-31 0000315545 us-gaap:WarrantMember 2020-01-01 2020-12-31 0000315545 us-gaap:WarrantMember 2020-12-31 0000315545 us-gaap:WarrantMember 2021-01-01 2021-12-31 0000315545 us-gaap:WarrantMember 2021-12-31 0000315545 2021-08-29 2021-08-30 0000315545 PVCT:BoardMembersMember 2020-12-31 0000315545 PVCT:BoardMembersMember 2020-01-01 2020-12-31 0000315545 PVCT:BoardMembersMember 2021-12-31 0000315545 PVCT:BoardMembersMember 2021-01-01 2021-12-31 0000315545 PVCT:RangeOneMember 2021-12-31 0000315545 PVCT:RangeOneMember 2021-01-01 2021-12-31 0000315545 PVCT:RangeTwoMember 2021-12-31 0000315545 PVCT:RangeTwoMember 2021-01-01 2021-12-31 0000315545 PVCT:RangeThreeMember 2021-12-31 0000315545 PVCT:RangeThreeMember 2021-01-01 2021-12-31 0000315545 PVCT:RangeFourMember 2021-12-31 0000315545 PVCT:RangeFourMember 2021-01-01 2021-12-31 0000315545 PVCT:RangeFiveMember 2021-12-31 0000315545 PVCT:RangeFiveMember 2021-01-01 2021-12-31 0000315545 PVCT:RangeSixMember 2021-12-31 0000315545 PVCT:RangeSixMember 2021-01-01 2021-12-31 0000315545 PVCT:RangeSevenMember 2021-12-31 0000315545 PVCT:RangeSevenMember 2021-01-01 2021-12-31 0000315545 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0000315545 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0000315545 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0000315545 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0000315545 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0000315545 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0000315545 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0000315545 us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0000315545 PVCT:RangeOneMember us-gaap:WarrantMember 2021-12-31 0000315545 PVCT:RangeOneMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0000315545 PVCT:RangeTwoMember us-gaap:WarrantMember 2021-12-31 0000315545 PVCT:RangeTwoMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0000315545 PVCT:RangeThreeMember us-gaap:WarrantMember 2021-12-31 0000315545 PVCT:RangeThreeMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0000315545 PVCT:RangeFourMember us-gaap:WarrantMember 2021-12-31 0000315545 PVCT:RangeFourMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0000315545 PVCT:FederalCountryMember 2021-12-31 0000315545 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:AustralianTaxAuthorityMember 2021-12-31 0000315545 PVCT:BetweenTwoThousandAndTwentyTwoAndTwoThousandAndThirtySevenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:BetweenTwoThousandTwentyTwoAndTwoThousandThirtySixMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandAndTwoMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndTwoMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandAndThreeMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndThreeMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandAndFourMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndFourMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandAndFiveMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndFiveMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandAndSixMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndSixMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandAndSevenMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndSevenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandAndEightMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndEightMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandAndNineMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndNineMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandTenMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandTenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandElevenMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandElevenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandTwelveMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandTwelveMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandThirteenMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandThirteenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandFourteenMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandFourteenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandFifteenMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandFifteenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandSixteenMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandSixteenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandSeventeenMember PVCT:FederalCountryMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandSeventeenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandEighteenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandNineteenMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandTwentyMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandTwentyOneMember PVCT:FederalCountryMember 2021-12-31 0000315545 PVCT:TwoThousandAndSevenMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndSevenMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandAndEightMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndEightMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandAndNineMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandAndNineMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandTenMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandTenMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandElevenMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandElevenMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandTwelveMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandTwelveMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandThirteenMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandThirteenMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandFourteenMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandFourteenMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandFifteenMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandFifteenMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandSixteenMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandSixteenMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandSeventeenMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandSeventeenMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandEighteenMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandEighteenMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandNineteenMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandNineteenMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandTwentyMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandTwentyMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandTwentyOneMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000315545 PVCT:TwoThousandTwentyOneMember us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000315545 PVCT:TwoThousandSeventeenMember PVCT:AustralianTaxAuthorityMember 2021-12-31 0000315545 PVCT:TwoThousandEighteenMember PVCT:AustralianTaxAuthorityMember 2021-12-31 0000315545 PVCT:TwoThousandNineteenMember PVCT:AustralianTaxAuthorityMember 2021-12-31 0000315545 PVCT:TwoThousandTwentyMember PVCT:AustralianTaxAuthorityMember 2021-12-31 0000315545 PVCT:TwoThousandTwentyOneMember PVCT:AustralianTaxAuthorityMember 2021-12-31 0000315545 PVCT:KnoxvilleTennesseeMember 2021-12-31 0000315545 PVCT:KnoxvilleTennesseeMember 2021-01-01 2021-12-31 0000315545 2021-07-01 2021-12-31 0000315545 us-gaap:PropertySubjectToOperatingLeaseMember 2021-01-01 2021-12-31 0000315545 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000315545 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0000315545 us-gaap:PropertySubjectToOperatingLeaseMember 2020-01-01 2020-12-31 0000315545 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000315545 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0000315545 2021-10-25 0000315545 us-gaap:SubsequentEventMember 2022-02-20 2022-02-23 iso4217:USD shares iso4217:USD shares pure utr:sqft PVCT:Australian 0000315545 false FY

P5Y

10-K true 2021-12-31 --12-31 2021 false 001-36457 PROVECTUS BIOPHARMACEUTICALS, INC. DE 90-0031917 10025 Investment Drive Suite 250 Knoxville TN 37932 866 594-5999 No No Yes Yes Non-accelerated Filer true false false false 26775067 419447119 The information required by Part III is incorporated by reference to portions of the definitive proxy statement to be filed within 120 days after December 31, 2021, pursuant to Regulation 14A under the Securities Exchange Act of 1934 in connection with the 2022 annual meeting of stockholders. 688 Marcum LLP Los Angeles, CA

682984

97231

2423958

5107

3930

329908

322518

3441957

423679

91178

78313

31836

44701

39563

120821

3513356

589201

1287459

956860

150000 2500000

2002486

1500782

10578

2774968

6044 1766493 238452 236228

1260000

16622000

200000

6770000

45617

84383

7700636

30711714

39061

44783

7700636

30795558

0.001

25000000

240000

100

3500

12374000

12373247

14164889

12373

9441000

9218449

105532804

9219

0.001

1000000000

419447119

398807037

419447

398808

241440106

209923347

-34467

-34097

-246033958

-240494415

-4187280

-30206357

3513356

589201

2608357

2812760

2063897

2150816

4672254

4963576

-4672254

-4963576

-3000 31315 27694

3415

63094

961702

1748120

-867289

-1714011

-5539543

-6677587

-0.01

-0.02

408223004

393252321

-5539543

-6677587

-370

-10089

-5539913

-6687676

100

389889475

389889

209378835

-24008

-233816828

-24072112

7855062 7856 410821 418677

64294

1062500

1063

68025

69088

1372

-6677587

-10089

100

398807037

398808

209923347

-34097

-240494415

-30206357

100

398807037

398808

209923347

-34097

-240494415

-30206357

18052966 18053 944170 962223

300000

300

22899

23199

488

-100

65666

-65

12373247 12373 3528849 3541222 9440594 9441 27022417 27031858 -222145 -222 2221450 2221 -1999

-5539543

-370

12373247

12373

9218449

9219

419447119

419447

241440106

-34467

-246033958

-4187280

12373247

12373

9218449

9219

419447119

419447

241440106

-34467

-246033958

-4187280

-5539543

-6677587

23688

134754

81258 73579

12865

13683

228107

63094

1449

-50321

-265957

-347107

331148

-170413

-2500000

502581

244887

-83549

-77916

956834

1747683

-1013304

-4085795

2960000

3125000

200000 100000

248177

105985

62500

150000

962223

418676

4024046

3600191

-1031

-7871

3009711

-493475

97231

590706

3106942

97231

682984

97231

2423958

3106942

97231

273347 318775 3541222 27031858 222

1. Business Organization and Nature of Operations Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases, with the aim of maximizing the curative impact of these medicines and achieving immunity from treated disease. These investigational drugs are based on a wholly owned class of small molecules called halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal sodium (“RBS”). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Oncology: PV-10®, an investigational cancer immunotherapy administered by intralesional (“IL”) injection and an injectable formulation of cGMP (“current Good Manufacturing Practice”) RBS, is undergoing clinical study for adult solid tumor cancers, such as melanoma and gastrointestinal (“GI”) tumors (including hepatocellular carcinoma (“HCC”), colorectal cancer metastatic to the liver (“mCRC”), neuroendocrine tumors (“NET”) metastatic to the liver (“mNET”), and uveal melanoma metastatic to the liver (“mUM”), among others). Orphan drug designation (“ODD”) status was granted to PV-10 by the FDA for metastatic melanoma in 2006, HCC in 2011, and ocular melanoma (including uveal melanoma) in 2019. Oral formulations of cGMP RBS are also undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor cancers, such as head and neck, breast, colorectal, and testicular cancers. In vivo data of a colorectal tumor murine model that continuously promotes abnormal cell proliferation and transformation into cancer indicate increased survival in both prophylactic and therapeutic settings.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pediatric Oncology: IL PV-10 is also undergoing preclinical study for pediatric solid tumor cancers (including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma). ODD status was granted to PV-10 by the FDA for neuroblastoma in 2018.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Hematology: Oral formulations of cGMP RBS are undergoing preclinical study for refractory and relapsed pediatric blood cancers (including leukemias). In vivo data of an acute lymphoblastic leukemia murine model indicated increased survival.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Virology: Systemically administered formulations of cGMP RBS are undergoing preclinical study for the novel strain of coronavirus (“CoV”): severe acute respiratory syndrome (“SARS”) CoV 2 (“SARS-CoV-2”). In silico data indicate docking-based binding affinity to SARS-CoV-2’s main protease, spike protein, and different variants of the spike protein. In vitro data indicate activity against SARS-CoV-2 in African green monkey kidney cell (Vero) and human lung epithelial cell (Calu-3) models, and synergistic activity with remdesivir in a Vero cell model.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Microbiology: Different formulations of cGMP RBS are undergoing preclinical study as potential treatments for multi-drug resistant (“MDR”) bacteria, such as gram-positive and gram-negative.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Ophthalmology: Topical formulations of cGMP RBS are undergoing preclinical study as potential treatments for diseases of the eye, such as infectious keratitis.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dermatology: PH-10®, an investigational immuno-dermatology agent administered as a topical gel and formulation of cGMP RBS, is undergoing monotherapy clinical study and preclinical study of combination therapy with approved drugs for inflammatory dermatoses (including psoriasis and atopic dermatitis).</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Animal Health: Different formulations of cGMP RBS are undergoing development as potential treatments for animal cancers and dermatological disorders.</td></tr> </table> To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. SARS-CoV-2 was reportedly first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at December 31, 2021. The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is still uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials; disrupt the Company’s regulatory activities; and/or have other adverse effects on the Company’s clinical development.

2. Liquidity and Going Concern The Company’s cash, cash equivalents, and restricted cash were $<span id="xdx_902_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iI_c20211231_zlBj3WzPriQi" title="Cash, cash equivalents, and restricted cash">3,106,942 at December 31, 2021 which includes the $2,423,958 of restricted cash resulting from a grant received from the State of Tennessee. The Company’s working capital deficiency was $4,258,679 and $30,288,035 as of December 31, 2021 and 2020, respectively. The improvement in working capital is primarily driven by the conversion of the 2017 and 2020 Notes into Series D and D-1 Preferred Stock. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10, PH-10, and/or any other halogenated xanthene-based drug products, and to raise additional capital. The Company plans to access capital resources through possible public or private equity offerings, including the 2021 Financing (as defined in Note 5), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity and debt offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2022 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

3106942

2423958

-4258679 -30288035

3. Significant Accounting Policies Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of December 31, 2021 and 2020, the Company’s cash equivalents consist of Treasury bills. <p id="xdx_844_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zmFzHWG11Ja3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Restricted Cash Restricted cash consists of a grant award of $2,500,000 received in cash from the State of Tennessee less payments to vendors for expenses and deposits in the amount of $76,042. See Note 14. Grants. Cash Concentrations Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. As of December 31, 2021 and 2020, the Company had cash, cash equivalent, and restricted cash balances in excess of FDIC insurance limits of $2,856,942 and $0, respectively. Equipment and Furnishings, net Equipment and furnishings are stated at cost less accumulated depreciation. Depreciation of equipment is provided for using the straight-line method over the estimated useful lives of the assets. Computers and office equipment are being depreciated over five years; furniture and fixtures are being depreciated over ten years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets. Long-Lived Assets The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell. Management has determined there to be no impairment during the years ended December 31, 2021 and 2020. Patent Costs, net Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining estimated useful life of the patent. The patents are fully amortized as of December 31, 2021 and 2020. Patent amortization was $0 and $228,107 during the years ended December 31, 2021 and 2020, respectively. Related Party Receivables Management estimates the reserve for uncollectibility based on existing economic conditions, the financial conditions of the current and former employees, and the amount and age of past due receivables. Receivables are considered past due if full payment is not received by the contractual due date. Past due amounts are generally written off against the reserve for uncollectibility only after all collection attempts have been exhausted. See Note 8 – Short-term Receivables. Grant Income Grant income is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as unearned grant revenue and recognized as other income when qualifying costs are incurred. Research and Development Research and development costs are charged to expense when incurred. An allocation of payroll expenses to research and development is made based on a percentage estimate of time spent. The research and development costs include the following: payroll, consulting and contract labor, lab supplies and pharmaceutical preparations, insurance, rent and utilities, and depreciation and amortization. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of operating lease right-of-use (“ROU”) assets and lease liabilities on the balance sheet (“ASC 842”) with amendments issued in 2018. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company is also required to recognize and measure new leases at the adoption date and recognize a cumulative-effect adjustment in the period of adoption using a modified retrospective approach, with certain practical expedients available. The Company adopted ASC 842 effective January 1, 2019 and elected to apply the available practical expedients. The standard had an impact on the Company’s consolidated balance sheets but did not have a material impact on the Company’s consolidated statements of operations or cash flows upon adoption. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases. Income Taxes The Company accounts for income taxes under the liability method in accordance with Accounting Standards Codification (“ASC”) 740 “Income Taxes”. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established if it is more likely than not that all, or some portion, of deferred income tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset would increase income in the period such determination was made. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. Any recognized income tax positions would be measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement would be reflected in the period in which the change in judgment occurs. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There were no income taxes, interest or penalties incurred in 2021 or 2020. Convertible Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with ASC Topic 815: Derivatives and Hedging. The accounting treatment of derivative financial instruments requires that the Company record qualifying embedded conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Embedded conversion options classified as derivative liabilities and any related equity classified freestanding instruments are recorded as a discount to the host instrument. If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument. Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ deficiency. Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: <p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2X68G7pN5gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 0.25in"> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 16%; text-align: right" title="Total potentially dilutive shares">512,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 16%; text-align: right" title="Total potentially dilutive shares">87,264,164</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td>Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zbYd32ujd7W4" style="text-align: right" title="Total potentially dilutive shares">3,625,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Total potentially dilutive shares">4,800,000</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible preferred stock</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares">104,557,737</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares">65,663</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total potentially dilutive shares</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">108,695,237</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">92,129,827</td><td style="text-align: left"> </td></tr> </table> Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The Company determines the estimated fair value of amounts presented in these consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of December 31, 2021 and 2020. The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, restricted cash, receivables, other current assets, accounts payable, unearned grant income, and accrued expenses approximate fair values due to the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.65in">Level 1</td> <td style="width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability.</td></tr> </table> In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Foreign Currency Translation The Company’s reporting currency is the United States Dollar. The functional currencies of the Company’s operating subsidiaries are their local currencies (United States Dollar and Australian Dollar). Australian Dollar denominated assets and liabilities are translated into the United States Dollar at the balance sheet date ($22,053 and $407,851 at December 31, 2021 and $10,552 and $332,446 at December 31, 2020, respectively), and expense and other income accounts are translated at a weighted average exchange rate for the years then ended ($85,052 and $44,994 for the years ended December 31, 2021 and 2020, respectively). Equity is translated at historical rates and the resulting foreign currency translation adjustments are included as a component of accumulated other comprehensive loss (“AOCL”), which is a separate component of stockholders’ deficiency. Therefore, the U.S. dollar value of the non-equity translated items in the Company’s consolidated financial statements will fluctuate from period to period, depending on the changing value of the U.S. dollar versus these currencies. The Company engages in foreign currency denominated transactions with its Australian subsidiary. At the date that the transaction is recognized, each asset, liability, revenue, expense, gain or loss arising from the transaction is measured and recorded in the functional currency of the recording entity using the exchange rate in effect at that date. At each balance sheet date, recorded monetary balances denominated in a currency other than the functional currency are adjusted using the exchange rate at the balance sheet date, with gains or losses recorded in other income or other expense. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company computes the fair value of equity-classified warrants and options granted using the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock which is determined by reviewing its historical public market closing prices. Recently Issued Accounting Pronouncements In August 2020, FASB issued Accounting Standards Update (“ASU”) No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. The Company is currently evaluating the effect of the adoption of ASU 2020-06 will have on its consolidated financial statements and related disclosures. In October 2020, the FASB issued ASU 2020-10 “Codification Improvements”, which improves consistency by amending the Codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. The guidance is effective for the Company beginning in the first quarter of fiscal year 2022 with early adoption permitted. The Company adopted this standard on January 1, 2022 and it did not have a material effect on its consolidated financial statements. On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company adopted this standard on January 1, 2022 and it did not have a material effect on its consolidated financial statements. Recent Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (“ASC”) Topic 740, Income Taxes. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The Company adopted ASU 2019-12 on January 1, 2021 and there was no material impact on the Company’s consolidated financial statements or disclosures. In January 2020, the FASB issued ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. 20 The Company adopted ASU 2020-01 on a prospective basis on January 1, 2021 and there was no material impact on the Company’s consolidated financial statements or disclosures. In March 2020, the FASB issued ASU No. 2020-03, “Codification Improvements to Financial Instruments” (“ASU 2020-03”). There are seven issues addressed in this update. Issues 1 – 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the Company. Issue 6 was a clarification on determining the contractual term of a net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the Company. Issue 7 relates to the regaining control of financial assets sold and the recordation of an allowance for credit losses. The amendment related to issues 1, 2, 4 and 5 became effective immediately upon adoption of the update. Issue 3 becomes effective for fiscal years beginning after December 15, 2019. Issues 6 and 7 become effective on varying dates that relate to the dates of adoption of other updates. The Company adopted the applicable provisions within ASU 2020-03 which became effective during fiscal 2020 and 2021 and this adoption did not have a material impact on the Company’s consolidated financial statements and financial statement disclosures.

Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets.

Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of December 31, 2021 and 2020, the Company’s cash equivalents consist of Treasury bills.

<p id="xdx_844_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zmFzHWG11Ja3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Restricted Cash Restricted cash consists of a grant award of $2,500,000 received in cash from the State of Tennessee less payments to vendors for expenses and deposits in the amount of $76,042. See Note 14. Grants.

2500000 76042 Cash Concentrations Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. As of December 31, 2021 and 2020, the Company had cash, cash equivalent, and restricted cash balances in excess of FDIC insurance limits of $2,856,942 and $0, respectively. 2856942 0

Equipment and Furnishings, net Equipment and furnishings are stated at cost less accumulated depreciation. Depreciation of equipment is provided for using the straight-line method over the estimated useful lives of the assets. Computers and office equipment are being depreciated over five years; furniture and fixtures are being depreciated over ten years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.

Long-Lived Assets The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell. Management has determined there to be no impairment during the years ended December 31, 2021 and 2020.

Patent Costs, net Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining estimated useful life of the patent. The patents are fully amortized as of December 31, 2021 and 2020. Patent amortization was $0 and $228,107 during the years ended December 31, 2021 and 2020, respectively. Related Party Receivables Management estimates the reserve for uncollectibility based on existing economic conditions, the financial conditions of the current and former employees, and the amount and age of past due receivables. Receivables are considered past due if full payment is not received by the contractual due date. Past due amounts are generally written off against the reserve for uncollectibility only after all collection attempts have been exhausted. See Note 8 – Short-term Receivables.

228107

Grant Income Grant income is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as unearned grant revenue and recognized as other income when qualifying costs are incurred.

Research and Development Research and development costs are charged to expense when incurred. An allocation of payroll expenses to research and development is made based on a percentage estimate of time spent. The research and development costs include the following: payroll, consulting and contract labor, lab supplies and pharmaceutical preparations, insurance, rent and utilities, and depreciation and amortization.

Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of operating lease right-of-use (“ROU”) assets and lease liabilities on the balance sheet (“ASC 842”) with amendments issued in 2018. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company is also required to recognize and measure new leases at the adoption date and recognize a cumulative-effect adjustment in the period of adoption using a modified retrospective approach, with certain practical expedients available. The Company adopted ASC 842 effective January 1, 2019 and elected to apply the available practical expedients. The standard had an impact on the Company’s consolidated balance sheets but did not have a material impact on the Company’s consolidated statements of operations or cash flows upon adoption. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

Income Taxes The Company accounts for income taxes under the liability method in accordance with Accounting Standards Codification (“ASC”) 740 “Income Taxes”. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established if it is more likely than not that all, or some portion, of deferred income tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset would increase income in the period such determination was made. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. Any recognized income tax positions would be measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement would be reflected in the period in which the change in judgment occurs. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There were no income taxes, interest or penalties incurred in 2021 or 2020.

0.50

Convertible Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with ASC Topic 815: Derivatives and Hedging. The accounting treatment of derivative financial instruments requires that the Company record qualifying embedded conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Embedded conversion options classified as derivative liabilities and any related equity classified freestanding instruments are recorded as a discount to the host instrument. If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument.

Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ deficiency.

Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: <p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2X68G7pN5gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 0.25in"> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 16%; text-align: right" title="Total potentially dilutive shares">512,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 16%; text-align: right" title="Total potentially dilutive shares">87,264,164</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td>Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zbYd32ujd7W4" style="text-align: right" title="Total potentially dilutive shares">3,625,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Total potentially dilutive shares">4,800,000</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible preferred stock</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares">104,557,737</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares">65,663</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total potentially dilutive shares</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">108,695,237</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">92,129,827</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2X68G7pN5gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 0.25in"> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 16%; text-align: right" title="Total potentially dilutive shares">512,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 16%; text-align: right" title="Total potentially dilutive shares">87,264,164</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td>Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zbYd32ujd7W4" style="text-align: right" title="Total potentially dilutive shares">3,625,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Total potentially dilutive shares">4,800,000</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible preferred stock</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares">104,557,737</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares">65,663</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total potentially dilutive shares</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">108,695,237</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">92,129,827</td><td style="text-align: left"> </td></tr> </table>

512500

87264164

3625000

4800000

104557737

65663

108695237

92129827

Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The Company determines the estimated fair value of amounts presented in these consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of December 31, 2021 and 2020. The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, restricted cash, receivables, other current assets, accounts payable, unearned grant income, and accrued expenses approximate fair values due to the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.65in">Level 1</td> <td style="width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability.</td></tr> </table> In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

Foreign Currency Translation The Company’s reporting currency is the United States Dollar. The functional currencies of the Company’s operating subsidiaries are their local currencies (United States Dollar and Australian Dollar). Australian Dollar denominated assets and liabilities are translated into the United States Dollar at the balance sheet date ($22,053 and $407,851 at December 31, 2021 and $10,552 and $332,446 at December 31, 2020, respectively), and expense and other income accounts are translated at a weighted average exchange rate for the years then ended ($85,052 and $44,994 for the years ended December 31, 2021 and 2020, respectively). Equity is translated at historical rates and the resulting foreign currency translation adjustments are included as a component of accumulated other comprehensive loss (“AOCL”), which is a separate component of stockholders’ deficiency. Therefore, the U.S. dollar value of the non-equity translated items in the Company’s consolidated financial statements will fluctuate from period to period, depending on the changing value of the U.S. dollar versus these currencies. The Company engages in foreign currency denominated transactions with its Australian subsidiary. At the date that the transaction is recognized, each asset, liability, revenue, expense, gain or loss arising from the transaction is measured and recorded in the functional currency of the recording entity using the exchange rate in effect at that date. At each balance sheet date, recorded monetary balances denominated in a currency other than the functional currency are adjusted using the exchange rate at the balance sheet date, with gains or losses recorded in other income or other expense.

22053 407851 10552 332446 85052 44994

Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company computes the fair value of equity-classified warrants and options granted using the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock which is determined by reviewing its historical public market closing prices.

Recently Issued Accounting Pronouncements In August 2020, FASB issued Accounting Standards Update (“ASU”) No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. The Company is currently evaluating the effect of the adoption of ASU 2020-06 will have on its consolidated financial statements and related disclosures. In October 2020, the FASB issued ASU 2020-10 “Codification Improvements”, which improves consistency by amending the Codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. The guidance is effective for the Company beginning in the first quarter of fiscal year 2022 with early adoption permitted. The Company adopted this standard on January 1, 2022 and it did not have a material effect on its consolidated financial statements. On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company adopted this standard on January 1, 2022 and it did not have a material effect on its consolidated financial statements.

Recent Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (“ASC”) Topic 740, Income Taxes. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The Company adopted ASU 2019-12 on January 1, 2021 and there was no material impact on the Company’s consolidated financial statements or disclosures. In January 2020, the FASB issued ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. 20 The Company adopted ASU 2020-01 on a prospective basis on January 1, 2021 and there was no material impact on the Company’s consolidated financial statements or disclosures. In March 2020, the FASB issued ASU No. 2020-03, “Codification Improvements to Financial Instruments” (“ASU 2020-03”). There are seven issues addressed in this update. Issues 1 – 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the Company. Issue 6 was a clarification on determining the contractual term of a net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the Company. Issue 7 relates to the regaining control of financial assets sold and the recordation of an allowance for credit losses. The amendment related to issues 1, 2, 4 and 5 became effective immediately upon adoption of the update. Issue 3 becomes effective for fiscal years beginning after December 15, 2019. Issues 6 and 7 become effective on varying dates that relate to the dates of adoption of other updates. The Company adopted the applicable provisions within ASU 2020-03 which became effective during fiscal 2020 and 2021 and this adoption did not have a material impact on the Company’s consolidated financial statements and financial statement disclosures. 4. Other Accrued Expenses The following table summarizes the other accrued expenses at December 31, 2021 and 2020: Schedule of Other Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none"> <td> </td><td> </td> <td colspan="2" id="xdx_496_20211231_z4aEdhbpgDV4" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" id="xdx_49F_20201231_zuwzVfru4Oig" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td> </td></tr> <tr> <td> </td><td> </td> <td colspan="6" style="text-align: center">For The Years Ended</td><td> </td></tr> <tr> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td> </td></tr> <tr> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td> </td></tr> <tr id="xdx_407_eus-gaap--AccruedPayrollTaxesCurrent_iI_maOALCzSrO_zMyazBRL7Hzc" style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued payroll and taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">174,533</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">31,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedVacationCurrent_iI_maOALCzSrO_zknb9Q95bjGg" style="background-color: White"> <td style="text-align: left">Accrued vacation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,871</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,452</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOALCzSrO_z1ZykeazD1Zh" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued directors’ fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,560,589</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,175,589</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccruedPppInterest_iI_maOALCzSrO_zxc4EigqdQIh" style="background-color: White"> <td style="text-align: left">Accrued PPP interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">438</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedOtherExpenses_iI_maOALCzSrO_zDllp6AxT9y1" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued other expenses</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">224,493</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">267,799</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtOALCzSrO_z1ZH7oMa2T0d" style="background-color: White"> <td style="text-align: left">Total Other Accrued Expenses</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,002,486</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,500,782</td><td style="text-align: left"> </td></tr> </table> The following table summarizes the other accrued expenses at December 31, 2021 and 2020: Schedule of Other Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none"> <td> </td><td> </td> <td colspan="2" id="xdx_496_20211231_z4aEdhbpgDV4" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" id="xdx_49F_20201231_zuwzVfru4Oig" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td> </td></tr> <tr> <td> </td><td> </td> <td colspan="6" style="text-align: center">For The Years Ended</td><td> </td></tr> <tr> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td> </td></tr> <tr> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td> </td></tr> <tr id="xdx_407_eus-gaap--AccruedPayrollTaxesCurrent_iI_maOALCzSrO_zMyazBRL7Hzc" style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued payroll and taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">174,533</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">31,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedVacationCurrent_iI_maOALCzSrO_zknb9Q95bjGg" style="background-color: White"> <td style="text-align: left">Accrued vacation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,871</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,452</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOALCzSrO_z1ZykeazD1Zh" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued directors’ fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,560,589</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,175,589</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccruedPppInterest_iI_maOALCzSrO_zxc4EigqdQIh" style="background-color: White"> <td style="text-align: left">Accrued PPP interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">438</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedOtherExpenses_iI_maOALCzSrO_zDllp6AxT9y1" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued other expenses</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">224,493</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">267,799</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtOALCzSrO_z1ZH7oMa2T0d" style="background-color: White"> <td style="text-align: left">Total Other Accrued Expenses</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,002,486</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,500,782</td><td style="text-align: left"> </td></tr> </table>

174533

31504

42871

25452

1560589

1175589

438 224493 267799

2002486

1500782

5. Convertible Notes Payable The following summarizes convertible note activity during the years ended December 31, 2021 and 2020: Schedule of Convertible Notes Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2017 Notes</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020 Notes</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021 Notes</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 44%">Balance at January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zSe2FsaqkoG9" style="width: 10%; text-align: right" title="Balance">20,067,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_z5eBe8wQVd85" style="width: 10%; text-align: right" title="Balance">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zaaKUAsJGGqb" style="width: 10%; text-align: right" title="Balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231_zTZTEG4NWvc8" style="width: 10%; text-align: right" title="Balance">20,167,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td>Issuances</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zekNMivMiFm9" style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_zDGwia1ZMsV6" style="border-bottom: Black 1.5pt solid; text-align: right">3,225,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zYmSdnzIm8vi" style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231_zqlcJ70Bp1Jd" style="border-bottom: Black 1.5pt solid; text-align: right">3,225,000</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td>Balance at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zjqa6igEUbic" style="text-align: right" title="Balance">20,067,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_zX75RihnIm2l" style="text-align: right" title="Balance">3,325,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zjxVjgMyfwA8" style="text-align: right" title="Balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231_z0NYGI6ij439" style="text-align: right" title="Balance">23,392,000</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td>Issuances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zcV1x0sNOd02" style="text-align: right" title="Issuances">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_zcmXJdD7iUah" style="text-align: right" title="Issuances">1,700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zcQS0ulR5Qi4" style="text-align: right" title="Issuances">1,460,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231_zuhILhLAX80k" style="text-align: right" title="Issuances">3,160,000</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td>Conversions</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_di_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zEibzeCHAUS2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversions">(20,067,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_di_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_zYbWVhFHLoD3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversions">(5,025,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_di_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_z1J0C7rVoGUi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversions">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_di_c20210101__20211231_zMkIhgCtRhH5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversions">(25,092,000</td><td style="text-align: left">)</td></tr> <tr style="background-color: White"> <td>Balance at December 31, 2021</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zo7gozJ73hOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_zWNUyvDER2T4" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zCQKMIsMfpg6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">1,460,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231_zzL5WJDxrhX6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">1,460,000</td><td style="text-align: left"> </td></tr> </table> 2021 Financing On August 13, 2021, the Board approved a Financing Term Sheet (the “2021 Term Sheet”), which set forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $<span id="xdx_901_ecustom--FinancingArrangementAmount_iI_pp0p0_c20210813__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneFinancingMember__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardFirstAndFinalTrancheMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zqNDkhjMbi8i" title="Financing arrangement amount">5,000,000 (the “2021 Financing”), which amounts will be obtained in several tranches. Pursuant to the 2021 Term Sheet, the 2021 Notes will either be paid back, convert into shares of the Company’s Series D-1 Preferred Stock, or convert into Company equity securities and/or debt instruments of certain future financings on or before twelve months after the issue date of a 2021 Note, subject to certain exceptions. The 2021 Financing is in the form of unsecured convertible loans from the investors and evidenced by convertible promissory notes (individually, a “2021 Note” and collectively, the “2021 Notes”). In addition to customary provisions, the 2021 Notes will contain the following provisions: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The 2021 Notes will bear interest at the rate of eight percent (<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zn82Pt2Y6n1" title="Debt instrument, interest rate, stated percentage">8%) per annum on the outstanding principal amount of the loan that has been funded to the Company;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(ii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event there is a change of control of the Board, the term of the 2021 Notes will be accelerated and all amounts due under the 2021 Notes may be immediately due and payable at the investors’ option;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(iii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The outstanding principal amount and interest payment under the 2021 Notes may be paid back at maturity at the investors’ option;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(iv)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The outstanding principal amount and interest payable under the 2021 Notes may be convertible at the investors’ option into shares of Series D-1 Preferred Stock at a price per share equal to $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20211231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesD1ConvertiblePreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zfrIEbLfnQc7" title="Preferred stock price per shares">2.8620. The Series D-1 Preferred Stock is convertible into ten (<span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesD1ConvertiblePreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zpIF3zlVeVy6" title="Conversion of stock share issued">10) shares of common stock; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(v)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event the Company conducts a qualified equity or debt financing and the Company receives gross proceeds in the aggregate amount of $<span id="xdx_90F_ecustom--ProceedsFromDebtFinancingToConvert_pn6n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesD1ConvertiblePreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zzIwEqDXkmkc" title="Proceeds from debt financing to convert">20 million, the 2021 Notes may be converted into the equity securities and/or debt instruments of such financing at the same terms as those investors.</td></tr> </table> The embedded conversion options associated with the 2021 Notes do not require bifurcation and treatment as a derivative liability and they do not represent a beneficial conversion feature because the effective conversion price is not at a discount to the commitment date market price. As of December 31, 2021, the Company had received 2021 Notes (defined above) proceeds of $1,460,000, of which $200,000 is from a related party investor (an officer of the Company). 2020 Financing On December 31, 2019, the Board approved a Definitive Financing Term Sheet (the “2020 Term Sheet”), which sets forth the terms of a financing in the form of secured convertible loans from investors that were evidenced by convertible promissory notes (the “2020 Notes”), which bear interest at the rate of eight percent (8%) per annum. The outstanding principal amount and interest payable under the 2020 was convertible into shares of a new series of preferred stock at a price per share equal to $2.8620, either (a) at any time after the new series of preferred stock is designated, at the sole discretion of the investors; or (b) automatically on June 20, 2021, subject to certain exceptions. See 2021 Conversions of Notes into Preferred Stock below. Over time, the Company received 2020 Notes proceeds of $5,025,000, of which $100,000 is from a related party investor, an officer of the Company. 2017 Financing On March 23, 2017, the Company entered into an exclusive Definitive Financing Commitment Term Sheet with a group of the Company’s stockholders (the “PRH Group”), which was amended and restated effective as of March 19, 2017 (the “2017 Term Sheet”) that set forth the terms of a financing in the form of secured convertible loans from the PRH Group or other investors that were evidenced by convertible promissory notes (the “2017 Notes”), which bore interest at the rate of eight percent (8%) per annum. The outstanding principal amount and interest payable under the 2017 Notes were convertible into shares of a new series of preferred stock at a price per share equal to $0.2862, either (a) at any time after the new series of preferred stock is designated, at the sole discretion of the investors; or (b) automatically at the eighteen-month anniversary of the funding of the final tranche of 2017 Notes, subject to certain exceptions. See 2021 Conversions of Notes into Preferred Stock below. Over time, the Company received 2017 Notes proceeds of $20,067,000, of which $6,670,000 is from related party investors. Officers of the Company invested $3,050,000 and Board of Director members invested $3,620,000. Firm Commitment Previously, the Company had not designated the new series of preferred stock into which the 2017 Notes and the 2020 Notes (collectively the “Notes”) were convertible into. As a result, the Company did not analyze the Notes for a potential beneficial conversion feature, as the definition of a firm commitment had not been met since the Notes were not yet convertible. On June 17, 2021, the required Certificates of Designation were filed with the Delaware Secretary of State. Accordingly, a firm commitment was achieved. The Company analyzed the Notes for a beneficial conversion feature and determined that there was none because the Notes have an effective conversion price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--AwardTypeAxis__custom--FirmCommitmentMember__srt--RangeAxis__srt--MinimumMember_zzsd6UTGvqm2" title="Effective conversion price">0.2862 per share of underlying common stock, which exceeds the $0.07 per share commitment date closing market price of the common stock. 2021 Conversions of Notes into Preferred Stock <p id="xdx_893_ecustom--ScheduleOfConversionOfNotesIntoPreferredStockTableTextBlock_zAD6QYgiXM0i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The following summarizes the conversion activity during the year ended December 31, 2021: Schedule of Conversion of Notes into Preferred Stock <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021 Conversions Into Preferred Stock</td><td style="font-weight: bold"> </td></tr> <tr> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Series D</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Series D-1</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="text-align: center"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Principal converted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zZVtTvYBX6H9" style="width: 16%; text-align: right" title="Principal converted">2,712,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zmqdJhiMhpY5" style="width: 16%; text-align: right" title="Principal converted">22,380,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20211231_zAvTpldiDD17" style="width: 16%; text-align: right" title="Principal converted">25,092,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Accrued interest converted</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--AccruedInterestConverted_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zOFyZckSDQD3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Interest Converted">829,222</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--AccruedInterestConverted_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zPRhKaENfpC7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Interest Converted">4,651,858</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--AccruedInterestConverted_c20210101__20211231_zXrsXIe7iplg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Interest Converted">5,481,080</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total converted</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--DebtConversionConvertedInstrumentNet_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zgAD1itxIE16" style="text-align: right" title="Total converted">3,541,222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--DebtConversionConvertedInstrumentNet_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zKUF7ulYCCY" style="text-align: right">27,031,858</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--DebtConversionConvertedInstrumentNet_c20210101__20211231_z4x46fvS9dr4" style="text-align: right">30,573,080</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td>Conversion price</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zPZJ6Xjew7o2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion price">0.2862</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_z8H96NnqdtJf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion price">2.8620</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td>Shares</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_ziHwD5OTQwad" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares">12,373,247</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zNWwvHaGcn7a" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares">9,440,594</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231_zyMp3h80BNU3" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares">21,813,841</td><td style="text-align: left"> </td></tr> </table> Any fractional shares issuable pursuant to the formula were rounded up to the next whole share of Series D and Series D-1 Preferred Shares. The 2017 Notes originally provided that they were convertible into a new series of preferred stock at a price per share equal to $<span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionPrice_iI_uUSDPShares_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDAndD1ConvertiblePreferredStockMember__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenFinancingMember_z7oGLdc2KCva" title="Preferred stock conversion price">0.2862 (the “Original Conversion Price”). In order to ensure that the Company had sufficient authorized shares of preferred stock into which the 2017 Notes would convert, yet keep the economic terms of the 2017 Notes substantially equivalent, on February 26, 2019, the Company entered into amendments (the “Amendments”) to the 2017 Notes (as amended, the “Amended 2017 Notes”) with a large majority of the holders of 2017 Notes to increase the conversion price by 10 times from $<span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_uUSDPShares_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDAndD1ConvertiblePreferredStockMember__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenNotesMember__srt--RangeAxis__srt--MinimumMember_zv2DQfJQQ3zg">0.2862 to $<span id="xdx_900_eus-gaap--PreferredStockConvertibleConversionPrice_iI_uUSDPShares_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDAndD1ConvertiblePreferredStockMember__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenNotesMember__srt--RangeAxis__srt--MaximumMember_zDMdMhJkVTka">2.8620 (the “New Conversion Price”) and to change the conversion ratio by providing that one share of Preferred Stock would be convertible into 10 shares of common stock (the “New Conversion Ratio”). The impact of the Amendments was to reduce by 10 times the number of shares of preferred stock into which the 2017 Notes would convert, while keeping the economic terms the same. The 2020 Notes had substantially similar terms to the Amended 2017 Notes, including being convertible into preferred stock at the New Conversion Price, with the Preferred Stock being convertible into Common Stock at the New Conversion Ratio. In order to (i) address the fact that a small minority of the holders of 2017 Notes did not execute the Amendments and (ii) ensure economic fairness for all of the holders of the 2017 Notes and 2020 Notes, on June 17, 2021, the Company designated two separate series of preferred stock into which the 2017 Notes and 2020 Notes would convert: (i) the Company’s Series D Convertible Preferred Stock, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenFinancingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zysZGp9GnvBj">0.001 per share was designated for the holders of 2017 Notes who did not execute the Amendments and (ii) the Company’s Series D-1 Convertible Preferred Stock, par value $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenFinancingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zJKIapAtLSp3">0.001 per share was designated for the holders of Amended 2017 Notes and the holders of the 2020 Notes. On June 20, 2021, principal and interest in the aggregate amount of $<span id="xdx_90E_ecustom--DebtInstrumentPrincipalAndInterest_iI_c20210620__us-gaap--PlanNameAxis__custom--NonAmendedTwoThousandSeventeenFinancingMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndSeventeenNotesMember_zyEO1OJxl1u5" title="Aggregate outstanding principal and interest">3,541,222, representing all of the outstanding non-amended 2017 Notes, was converted into <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210619__20210620__us-gaap--PlanNameAxis__custom--NonAmendedTwoThousandSeventeenFinancingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndSeventeenNotesMember_zP9EzKVOdOBf">12,373,247 shares of Series D Convertible Preferred Stock at the Original Conversion Price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210620__us-gaap--PlanNameAxis__custom--NonAmendedTwoThousandSeventeenFinancingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndSeventeenNotesMember_zfc4lwuWy6Bh">0.2862. Further on June 20, 2021, principal and interest in the aggregate amount of $<span id="xdx_900_ecustom--DebtInstrumentPrincipalAndInterest_iI_c20210620__us-gaap--PlanNameAxis__custom--AmendedTwoThousandSeventeenFinancingMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndSeventeenNotesMember_zwP2bGzImSVc" title="Aggregate outstanding principal and interest">27,031,858, representing all of the outstanding Amended 2017 Notes and outstanding 2020 Notes was converted into <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210619__20210620__us-gaap--PlanNameAxis__custom--AmendedTwoThousandSeventeenFinancingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndSeventeenNotesMember_zO2twHbJaQbf">9,440,594 shares of Series D-1 Convertible Preferred Stock at the New Conversion Price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210620__us-gaap--PlanNameAxis__custom--AmendedTwoThousandSeventeenFinancingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndSeventeenNotesMember_z61BMDUTvWZg">2.862. Any fractional shares issuable pursuant to the formula were rounded up to the next whole share of Series D and Series D-1 Preferred Shares. See Note 9. Stockholders’ Deficiency for additional information on the Series D and Series D-1 Convertible Preferred Stock. As a result of the conversion of the 2017 Notes and 2020 Notes into convertible preferred stock, all the security interests of these Notes in the Company’s intellectual property were released.

The following summarizes convertible note activity during the years ended December 31, 2021 and 2020: Schedule of Convertible Notes Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2017 Notes</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020 Notes</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021 Notes</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 44%">Balance at January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zSe2FsaqkoG9" style="width: 10%; text-align: right" title="Balance">20,067,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_z5eBe8wQVd85" style="width: 10%; text-align: right" title="Balance">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zaaKUAsJGGqb" style="width: 10%; text-align: right" title="Balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231_zTZTEG4NWvc8" style="width: 10%; text-align: right" title="Balance">20,167,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td>Issuances</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zekNMivMiFm9" style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_zDGwia1ZMsV6" style="border-bottom: Black 1.5pt solid; text-align: right">3,225,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zYmSdnzIm8vi" style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231_zqlcJ70Bp1Jd" style="border-bottom: Black 1.5pt solid; text-align: right">3,225,000</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td>Balance at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zjqa6igEUbic" style="text-align: right" title="Balance">20,067,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_zX75RihnIm2l" style="text-align: right" title="Balance">3,325,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zjxVjgMyfwA8" style="text-align: right" title="Balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231_z0NYGI6ij439" style="text-align: right" title="Balance">23,392,000</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td>Issuances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zcV1x0sNOd02" style="text-align: right" title="Issuances">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_zcmXJdD7iUah" style="text-align: right" title="Issuances">1,700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zcQS0ulR5Qi4" style="text-align: right" title="Issuances">1,460,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231_zuhILhLAX80k" style="text-align: right" title="Issuances">3,160,000</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td>Conversions</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_di_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zEibzeCHAUS2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversions">(20,067,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_di_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_zYbWVhFHLoD3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversions">(5,025,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_di_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_z1J0C7rVoGUi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversions">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_di_c20210101__20211231_zMkIhgCtRhH5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversions">(25,092,000</td><td style="text-align: left">)</td></tr> <tr style="background-color: White"> <td>Balance at December 31, 2021</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandSeventeenNoteMember_zo7gozJ73hOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyNoteMember_zWNUyvDER2T4" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNoteMember_zCQKMIsMfpg6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">1,460,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231_zzL5WJDxrhX6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">1,460,000</td><td style="text-align: left"> </td></tr> </table>

20067000

100000

20167000

3225000

20067000

3325000

23392000

1700000

1460000

3160000

20067000

5025000

25092000

1460000

5000000

0.08

2.8620

20000000

1460000

200000

0.08

2.8620

5025000

100000

0.08

0.2862

20067000

6670000

3050000

3620000

0.2862

0.07

<p id="xdx_893_ecustom--ScheduleOfConversionOfNotesIntoPreferredStockTableTextBlock_zAD6QYgiXM0i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The following summarizes the conversion activity during the year ended December 31, 2021: Schedule of Conversion of Notes into Preferred Stock <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021 Conversions Into Preferred Stock</td><td style="font-weight: bold"> </td></tr> <tr> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Series D</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Series D-1</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="text-align: center"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Principal converted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zZVtTvYBX6H9" style="width: 16%; text-align: right" title="Principal converted">2,712,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zmqdJhiMhpY5" style="width: 16%; text-align: right" title="Principal converted">22,380,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20211231_zAvTpldiDD17" style="width: 16%; text-align: right" title="Principal converted">25,092,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Accrued interest converted</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--AccruedInterestConverted_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zOFyZckSDQD3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Interest Converted">829,222</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--AccruedInterestConverted_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zPRhKaENfpC7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Interest Converted">4,651,858</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--AccruedInterestConverted_c20210101__20211231_zXrsXIe7iplg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued Interest Converted">5,481,080</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total converted</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--DebtConversionConvertedInstrumentNet_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zgAD1itxIE16" style="text-align: right" title="Total converted">3,541,222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--DebtConversionConvertedInstrumentNet_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zKUF7ulYCCY" style="text-align: right">27,031,858</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--DebtConversionConvertedInstrumentNet_c20210101__20211231_z4x46fvS9dr4" style="text-align: right">30,573,080</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td>Conversion price</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zPZJ6Xjew7o2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion price">0.2862</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_z8H96NnqdtJf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion price">2.8620</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td>Shares</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_ziHwD5OTQwad" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares">12,373,247</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zNWwvHaGcn7a" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares">9,440,594</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231_zyMp3h80BNU3" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares">21,813,841</td><td style="text-align: left"> </td></tr> </table>

2712000

22380000

25092000

829222 4651858 5481080 3541222 27031858 30573080

0.2862

2.8620

12373247

9440594

21813841

0.2862

2.8620

0.001

3541222

12373247

0.2862

27031858

9440594

2.862

6. Notes Payable On April 20, 2020, the Company received a $62,500 loan under the CARES Act PPP (the “PPP Loan”). The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses. On May 20, 2021, the Company applied for forgiveness of the PPP Loan. On June 2, 2021, the Company was awarded full forgiveness of the PPP Loan and accrued interest. During the year ended December 31, 2021, the Company recognized a gain on forgiveness of the PPP loan of $<span id="xdx_900_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember__us-gaap--AwardTypeAxis__custom--TheCARESActMember_zXvHZxp1zapj" title="Gain on forgiveness of PPP loan">62,500 and interest of $<span id="xdx_906_ecustom--GainFromForgivenessOfPppLoanInterest_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember__us-gaap--AwardTypeAxis__custom--TheCARESActMember_zu7208z5ckf4">594. The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of December 31, 2021 and December 31, 2020, the balance of the note payable was $238,452 and $212,790, respectively.

62500

The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses.

62500

594

238452

212790

7. Related Party Transactions During the years ended December 31, 2021 and 2020, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $169,600 and $254,400, respectively, for services rendered. Director fees for Mr. Horowitz for the year ending December 31, 2021 and 2020 were $<span id="xdx_904_eus-gaap--ProfessionalFees_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBruceHorowitzMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7N7KmCNXcBf">75,000 and $<span id="xdx_900_eus-gaap--ProfessionalFees_pp0p0_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBruceHorowitzMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zvmjPfnQLBt8">75,000, respectively. Accrued director fees for Mr. Horowitz as of December 31, 2021 and 2020 were $281,250 and $206,250, respectively. Total amount owed to Capital Strategist as of December 31, 2021 and 2020 were $<span id="xdx_90A_eus-gaap--ProfessionalFees_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBruceHorowitzMember__srt--TitleOfIndividualAxis__srt--DirectorMember__dei--LegalEntityAxis__custom--CapitalStrategistMember_z6TIUlLZ4CYa">127,200 and $<span id="xdx_902_eus-gaap--ProfessionalFees_pp0p0_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBruceHorowitzMember__srt--TitleOfIndividualAxis__srt--DirectorMember__dei--LegalEntityAxis__custom--CapitalStrategistMember_zoBSHs9qADw2">42,400, respectively. Mr. Horowitz serves as both COO and a Director. See Note 5 and Note 8 for details of other related party transactions. Director fees during the years ended December 31, 2021 and 2020 were $385,000 and $383,065, respectively. Accrued directors’ fees as of December 31, 2021 and 2020 were $1,560,589 and $1,175,589, respectively.

169600

254400

75000

281250

206250

127200

42400

385000

383065

1560589

1175589

<p id="xdx_808_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_znVBqeX0ayLi" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">8. Short-term Receivables Receivables at December 31, 2021 and 2020, include the Australian VAT tax credit and approximately $2,100,000 that is owed from Peter Culpepper. The Company has established a reserve of approximately $2,100,000 as of December 31, 2021 and 2020, which represents the amount Culpepper owes to the Company under the Derivative Lawsuit Settlement (excluding the amount of attorneys’ fees incurred in enforcing the terms of the Derivative Lawsuit Settlement).

2100000000000

9. Stockholders’ Deficiency Authorized Capital As of December 31, 2021, the Company was authorized to issue 1,000,000,000 shares of common stock, $0.001 par value, and 25,000,000 shares of preferred stock, $0.001 par value. The holders of the Company’s common stock are entitled to one vote per share. The preferred stock is designated as follows: <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z3tdOAqsGhsg" title="Preferred stock, shares authorized">240,000 shares to Series B Convertible Preferred Stock (the “Series B Preferred Stock”), <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z3T3RCmOfD3c" title="Preferred stock, shares authorized">12,374,000 shares to Series D Convertible Preferred Stock (the “Series D Preferred Stock”), and 9,441,000 shares of Series D-1 Convertible Preferred Stock (the “Series D-1 Preferred Stock”) and 2,945,000 shares undesignated. Series B Preferred Stock On August 25, 2016, the Company filed the Series B Certificate of Designation with the Delaware Secretary of State. The Series B Certificate of Designation provides for the issuance of the Series B Preferred Stock with a par value $0.001 per share and a stated value of $25.00 per share. The Series B Preferred Stock has no voting rights. The holders of Series B Preferred Stock are entitled to receive cumulative dividends at the rate of <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20160824__20160825__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSWhi0vx7qV8" title="Preferred stock, dividend percentage">8% per annum of the stated value per share, until the fifth anniversary of the date of issuance of the Series B Preferred Stock, at which time the Series B Preferred Stock automatically converts into common stock at the adjusted conversion price of $0.0533. During the year ended December 31, 2021, <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNTRERmbXCCf" title="Preferred stock, shares converted">100 shares of outstanding Series B Preferred Stock automatically converted, at the fifth-year anniversary of their issuance, into 65,666 shares of common stock, which represents $3,500 ($2,500 of stated value plus $1,000 of cumulative dividends) divided by the adjusted conversion price. Series D and Series D-1 Preferred Stock The rights, preferences and privileges of the Series D Preferred Stock and Series D-1 Preferred Stock (collectively, the “D-Series Preferred Stock”) are set forth in their respective Certificates of Designation. The Board of Directors of the Company approved each of the Certificates of Designation on June 14, 2021, and each Certificate of Designation was filed with the Delaware Secretary of State on June 17, 2021. The Series D Certificate of Designation established and designated 12,374,000 shares of Series D Preferred Stock. The Series D-1 Certificate of Designation established and designated 9,441,000 shares of Series D-1 Preferred Stock. On June 20, 2021, the Company issued 12,373,247 shares of Series D Preferred Stock upon the conversion of all of the outstanding 2017 Notes at the Original Conversion Price of $0.2862 and issued 9,440,594 shares of Series D-1 Preferred Stock upon the conversion of all outstanding Amended 2017 Notes and 2020 Notes at the New Conversion Price of $2.862. See Note 5. Convertible Notes Payable for additional information on the conversion. During the year ended December 31, 2021, the Company received consideration of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--RestrictedSeriesDOnePreferredStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zgsmJtVNBVF9">150,000 from an investor in exchange for an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--RestrictedSeriesDOnePreferredStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zMGy3NZMEJg5">52,411 shares of restricted Series D-1 Preferred Stock that have not yet been issued. During the year ended December 31, 2021, a holder of <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOnePreferredStockMember_zL0QEZjauF53" title="Shares on conversion">222,145 shares of Series D-1 Preferred Stock voluntarily converted the Preferred Stock into 2,221,450 shares of common stock. Rank The Series D Preferred Stock and the Series D-1 Preferred Stock rank pari passu with each other. The D-Series Preferred Stock rank senior to the Common Stock and any other class or series of the Company’s capital stock, the terms of which do not provide that shares of such class rank senior to, or pari passu with, the D-Series Preferred as to dividends and distributions upon a change of control transaction, or the liquidation, winding-up and dissolution of the Company. Dividends The D-Series Preferred Stock does not have any dividend preference but are entitled to receive, on a pari passu basis, dividends, if any, that are declared and paid on the common stock and any other class of the Company’s capital stock that ranks junior or on par to the D-Series Preferred Stock. Liquidation Preference Upon the occurrence of the liquidation, winding-up or dissolution of the Company or certain mergers, corporate reorganizations or sales of the Company’s assets (each, a “Company Event”), holders of D-Series Preferred Stock will be entitled to receive a liquidation preference before any distributions are made to holders of any other class or series of the Company’s capital stock junior to the D-Series Preferred Stock. If a Company Event occurs within two years of June 20, 2021 (the “Date of Issuance”), the holders of D-Series D Preferred Stock will receive, for each share of D-Series Preferred Stock, an amount in cash equal to the Original Issue Price (as defined in the respective Certificates of Designation) multiplied by four. If a Company Event occurs from and after the second anniversary of the Date of Issuance, the holders of D-Series Preferred Stock will receive, for each share of D-Series Preferred Stock, an amount in cash equal to the Original Issue Price multiplied by six. The Original Issue Price for the Series D Preferred Stock is $0.2862, and the Original Issue Price for the Series D-1 Preferred Stock is $2.862. Voting Rights Holders of shares of D-Series Preferred Stock will vote together with the holders of common stock as a single class. Each share of Series D Preferred Stock carries the right to one vote per share. Each share of Series D-1 Preferred Stock carries the right to ten votes per share. The Company is not permitted to amend, alter or repeal its Certificate of Incorporation or Bylaws in a manner adverse to the relative rights, preferences, qualifications, limitations or restrictions of the D-Series Preferred Stock without the affirmative vote of a majority of the votes entitled to be cast by holders of outstanding shares of D-Series Preferred Stock, voting together as a single class with each share of D-Series Convertible Preferred Stock having a number of votes equal to the number of shares of common stock then issuable upon conversion of such share of D-Series Preferred Stock. Conversion The Series D Preferred Stock is convertible at the option of the holders thereof into shares of common stock based on a one-for-one conversion ratio. The Series D-1 Preferred Stock is convertible at the option of the holders thereof into shares of common stock based on a one-for-ten conversion ratio. The conversion ratio of the D-Series Preferred Stock is subject to adjustment for stock splits and combinations, recapitalizations, reclassifications, reorganizations, mergers, and consolidations. The D-Series Preferred Stock will automatically convert into shares of common stock upon the fifth anniversary of the date of issuance. Common Stock Issuances During the year ended December 31, 2020, the Company issued 1,062,500 shares of immediately vested restricted common stock with an aggregate issuance date value of $69,088, which was recognized immediately as stock compensation within general and administrative expenses on the accompanying consolidated statements of operations. The following summarizes the Common Stock Issuances activity during the year ended December 31, 2020: Schedule of Common Stock Issuance Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Type</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Date</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Issuance</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Grant Date Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Contractor</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: right">4/1/2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200330__20200401__us-gaap--RelatedPartyTransactionAxis__custom--ContractorOneMember_z6Tc64WvTMwa" style="width: 18%; text-align: right">25,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20200330__20200401__us-gaap--RelatedPartyTransactionAxis__custom--ContractorOneMember_zaDPmzlxJY7f" style="width: 18%; text-align: right">1,150</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Advisory Board Member</td><td> </td> <td style="text-align: right">7/31/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200730__20200731__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberOneMember_zwwc3xCwZyyh" style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20200730__20200731__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberOneMember_zgYEmOk0sMA8" style="text-align: right">1,800</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advisory Board Member</td><td> </td> <td style="text-align: right">8/31/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200830__20200831__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberTwoMember_zEsK83QI6B85" style="text-align: right">12,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20200830__20200831__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberTwoMember_zqXasdngOJM7" style="text-align: right">1,013</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Advisory Board Member</td><td> </td> <td style="text-align: right">10/26/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20201025__20201026__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberThreeMember_zMiFPOAaem6e" style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20201025__20201026__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberThreeMember_zjvpK4BETg05" style="text-align: right">1,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Contractor</td><td> </td> <td style="text-align: right">11/10/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--ContractorTwoMember_zbrkARmRti8k" style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--ContractorTwoMember_zteWb5PB9JPf" style="text-align: right">1,625</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Employee</td><td> </td> <td style="text-align: right">11/10/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--EmployeeMember_zslGy1wvWsu1" style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--EmployeeMember_zIsKitTjMdI" style="text-align: right">3,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Board of Director</td><td> </td> <td style="text-align: right">11/10/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--BoardOfDirectorMember_zPbAH6lqL1F4" style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--BoardOfDirectorMember_zxp7EVLSHHCh" style="text-align: right">6,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Board of Director/Officer</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: right; padding-bottom: 1.5pt">11/10/2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--BoardofDirectorOfficerMember_zqvYlwPMF8Ug" style="border-bottom: Black 1.5pt solid; text-align: right">800,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--BoardofDirectorOfficerMember_z8y1H1qk3o0i" style="border-bottom: Black 1.5pt solid; text-align: right">52,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200101__20201231_ziUwiytjODAe" style="text-align: right" title="Share Based Compensation, Shares">1,062,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20200101__20201231_zGQ9VqlDc3b9" style="text-align: right" title="Share Based Compensation">69,088</td><td style="text-align: left"> </td></tr> </table> During the year ended December 31, 2021, the Company issued an aggregate of 300,000 shares of immediately vested restricted common stock with a grant date fair value of $23,199 for services. During the year ended December 31, 2021, the Company issued <span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zVEAcTPAlYD9" title="Common shares issued on conversion of stock">2,221,450 shares of common stock upon the voluntary conversion of Series D-1 Convertible Preferred Stock.

1000000000

0.001

25000000

0.001

one vote per share

240000

12374000

9441000

2945000

0.001

25.00

0.08

0.0533

100

65666

3500

2500

1000

12374000

9441000

12373247

0.2862

9440594

2.862

150000

52411

222145

2221450

0.2862

2.862

Each share of Series D Preferred Stock carries the right to one vote per share.

Each share of Series D-1 Preferred Stock carries the right to ten votes per share.

1062500

69088

The following summarizes the Common Stock Issuances activity during the year ended December 31, 2020: Schedule of Common Stock Issuance Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Type</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Date</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Issuance</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Grant Date Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Contractor</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: right">4/1/2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200330__20200401__us-gaap--RelatedPartyTransactionAxis__custom--ContractorOneMember_z6Tc64WvTMwa" style="width: 18%; text-align: right">25,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20200330__20200401__us-gaap--RelatedPartyTransactionAxis__custom--ContractorOneMember_zaDPmzlxJY7f" style="width: 18%; text-align: right">1,150</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Advisory Board Member</td><td> </td> <td style="text-align: right">7/31/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200730__20200731__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberOneMember_zwwc3xCwZyyh" style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20200730__20200731__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberOneMember_zgYEmOk0sMA8" style="text-align: right">1,800</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advisory Board Member</td><td> </td> <td style="text-align: right">8/31/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200830__20200831__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberTwoMember_zEsK83QI6B85" style="text-align: right">12,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20200830__20200831__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberTwoMember_zqXasdngOJM7" style="text-align: right">1,013</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Advisory Board Member</td><td> </td> <td style="text-align: right">10/26/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20201025__20201026__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberThreeMember_zMiFPOAaem6e" style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20201025__20201026__us-gaap--RelatedPartyTransactionAxis__custom--AdvisoryBoardMemberThreeMember_zjvpK4BETg05" style="text-align: right">1,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Contractor</td><td> </td> <td style="text-align: right">11/10/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--ContractorTwoMember_zbrkARmRti8k" style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--ContractorTwoMember_zteWb5PB9JPf" style="text-align: right">1,625</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Employee</td><td> </td> <td style="text-align: right">11/10/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--EmployeeMember_zslGy1wvWsu1" style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--EmployeeMember_zIsKitTjMdI" style="text-align: right">3,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Board of Director</td><td> </td> <td style="text-align: right">11/10/2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--BoardOfDirectorMember_zPbAH6lqL1F4" style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--BoardOfDirectorMember_zxp7EVLSHHCh" style="text-align: right">6,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Board of Director/Officer</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: right; padding-bottom: 1.5pt">11/10/2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--BoardofDirectorOfficerMember_zqvYlwPMF8Ug" style="border-bottom: Black 1.5pt solid; text-align: right">800,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20201109__20201110__us-gaap--RelatedPartyTransactionAxis__custom--BoardofDirectorOfficerMember_z8y1H1qk3o0i" style="border-bottom: Black 1.5pt solid; text-align: right">52,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200101__20201231_ziUwiytjODAe" style="text-align: right" title="Share Based Compensation, Shares">1,062,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20200101__20201231_zGQ9VqlDc3b9" style="text-align: right" title="Share Based Compensation">69,088</td><td style="text-align: left"> </td></tr> </table>

25000

1150

25000

1800

12500

1013

25000

1750

25000

1625

50000

3250

100000

6500

800000

52000

1062500

69088

300000

23199

2221450

<p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zHauAOLfQxPi" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">10. Stock Incentive Plan and Warrants The 2017 Amendment and Restatement of the Provectus Biopharmaceuticals, Inc. 2014 Equity Compensation Plan (the “2017 Equity Compensation Plan”) provides for the issuance of up to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityCompensationPlanMember__srt--RangeAxis__srt--MaximumMember_zkuC5hSAfQV4" title="Number of common stock issuable">20,000,000 shares of common stock pursuant to stock options for the benefit of eligible employees and directors of the Company. Options granted under the 2017 Equity Compensation Plan are either “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code or options which are not incentive stock options. The stock options are exercisable over a period determined by the Board of Directors (through its Compensation Committee), but generally no longer than <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityCompensationPlanMember__srt--RangeAxis__srt--MaximumMember_zPQph7tyZsr4" title="Stock options period">10 years after the date they are granted. As of December 31, 2021, there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityCompensationPlanMember_zXIPyPgGpnr5" title="Number of available for issuance">16,437,500 shares available for issuance under the 2017 Equity Compensation Plan. There were no stock options granted during the year ended December 31, 2021. During the year ended December 31, 2020, the Company issued <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20200101__20201231__srt--TitleOfIndividualAxis__custom--OfficerOrDirectorMember__us-gaap--VestingAxis__custom--FiveYearImmediatelyVestedMember_zuhrfbj5qoDd">2,425,000 <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtYxL_c20200101__20201231__srt--TitleOfIndividualAxis__custom--OfficerOrDirectorMember__us-gaap--VestingAxis__custom--FiveYearImmediatelyVestedMember_z3BWfdIlX3Xe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Stock options expiration period::XDX::P5Y">five-year immediately vested stock options to an officer/director to purchase an aggregate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20200101__20201231__srt--TitleOfIndividualAxis__custom--OfficerOrDirectorMember__us-gaap--VestingAxis__custom--FiveYearImmediatelyVestedMember_zz8wzXHGKCJ7">2,425,000 shares of common stock with an exercise price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__srt--TitleOfIndividualAxis__custom--OfficerOrDirectorMember__us-gaap--VestingAxis__custom--FiveYearImmediatelyVestedMember_z3awwzNmzyse" title="Exercise price">0.12 per share. The stock options had an aggregate grant date fair value of $<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200101__20201231__srt--TitleOfIndividualAxis__custom--OfficerOrDirectorMember__us-gaap--VestingAxis__custom--FiveYearImmediatelyVestedMember_zZVAs1zi5dcl" title="Aggregate grant date fair value">62,880, which was recognized immediately as stock compensation within general and administrative expenses on the accompanying consolidated statements of operations. During the year ended December 31, 2020, the Company issued <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20200101__20201231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--VestingAxis__custom--FiveYearImmediatelyVestedMember_zdTa9HnBNhH9" title="Stock options to purchase shares of common stock">100,000 <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtYxL_c20200101__20201231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--VestingAxis__custom--FiveYearImmediatelyVestedMember_zeEl3WS8X7ml" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Stock options expiration period::XDX::P5Y">five-year immediately vested stock options to a director to purchase an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20200101__20201231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--VestingAxis__custom--FiveYearImmediatelyVestedMember_zEkFGzdEiifa" title="Stock options to purchase shares of common stock">100,000 shares of common stock with an exercise price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--VestingAxis__custom--FiveYearImmediatelyVestedMember_zIWGdT4q3Nq3" title="Exercise price">0.2862 per share. The stock options had an aggregate grant date fair value of $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200101__20201231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--VestingAxis__custom--FiveYearImmediatelyVestedMember_zVjAnNvBwtgh" title="Aggregate grant date fair value">1,414, which was recognized immediately as stock compensation within general and administrative expenses on the accompanying consolidated statements of operations. <p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsqCjTRxTU49" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Stock options granted during the year ended December 31, 2020 were valued using the Black Scholes Model, with the following assumptions used: Schedule of Stock Options Granted Valued Using Black Scholes Model <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 0.5in"> <tr style="background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Expected terms (years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2.50</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93</td><td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.23</td><td style="text-align: left">%</td></tr> <tr style="background-color: White"> <td style="text-align: left">Expected dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zBZuk8hPCU34" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table summarizes option activity during the year ended December 31, 2021 and 2020: Summary of Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center">Weighted Average</td><td style="text-align: center; vertical-align: bottom"> </td> </tr> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Exercise Price</td><td style="text-align: center; vertical-align: bottom"> </td> </tr> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 68%">Outstanding and exercisable at January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20200101__20201231_z88MT9zognu" style="width: 12%; text-align: right" title="Number of Options Outstanding and exercisable, beginning balance">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zCwar8TqAi9i" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, beginning balance">0.88</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20201231_zLZRJdm0BCk8" style="text-align: right" title="Number of Options, Granted">2,525,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.20</td><td style="text-align: left"> </td> </tr> <tr style="background-color: White"> <td style="text-align: left; padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20200101__20201231_z8GZaG5oGyIf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(725,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">0.88</td><td style="text-align: left"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Outstanding and exercisable at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zWV0uGmodHAj" style="text-align: right" title="Number of Options Outstanding and exercisable, beginning balance">4,800,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zhvjVw2oEfue" style="text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, beginning balance">0.46</td><td style="text-align: left"> </td> </tr> <tr style="background-color: White"> <td style="text-align: left; padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20211231_zia3qgcme3gj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(1,175,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zaW4orEj6TK1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">0.89</td><td style="text-align: left"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Outstanding and exercisable at December 31, 2021</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_zLAbgTq6IM9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding and exercisable, ending balance">3,625,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zM52PvY69j7e" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, ending balance">0.32</td><td style="text-align: left"> </td> </tr> </table> As of December 31, 2021, the intrinsic value of outstanding and exercisable options was $0. <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z2rT16Yljby9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table summarizes information about stock options outstanding at December 31, 2021: Summary of Stock Options Outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center">Options Outstanding</td><td> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">Options Exercisable</td></tr> <tr> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Exercise Price</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Outstanding Number of Options</td><td style="text-align: center; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted Average Remaining Life In Years</td><td style="text-align: center; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Exercisable Number of Options</td></tr> <tr> <td colspan="2"> </td><td> </td><td> </td> <td> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pdd" style="width: 16%; text-align: right" title="Exercise price">0.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pdd" style="width: 26%; text-align: right" title="Number Outstanding">2,425,000</td><td style="width: 2%"> </td> <td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOJfBV0aF8m1" style="width: 26%; text-align: right" title="Weighted Average Remaining Contractual Life">3.90</td><td style="width: 2%"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pdd" style="width: 26%; text-align: right" title="Number Exercisable">2,425,000</td></tr> <tr style="background-color: White"> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pdd" style="text-align: right" title="Exercise price">0.29</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pdd" style="text-align: right" title="Number Outstanding">100,000</td><td> </td> <td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zOEDvii4LaW3" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.90</td><td> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pdd" style="text-align: right" title="Number Exercisable">100,000</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pdd" style="text-align: right" title="Exercise price">0.67</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pdd" style="text-align: right" title="Number Outstanding">200,000</td><td> </td> <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zn4QtkV1Dc98" style="text-align: right" title="Weighted Average Remaining Contractual Life">1.60</td><td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pdd" style="text-align: right" title="Number Exercisable">200,000</td></tr> <tr style="background-color: White"> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pdd" style="text-align: right" title="Exercise price">0.75</td><td style="text-align: left"> </td><td> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pdd" style="text-align: right" title="Number Outstanding">550,000</td><td> </td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zwGac4LnAkf" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.90</td><td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pdd" style="text-align: right" title="Number Exercisable">550,000</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pdd" style="text-align: right" title="Exercise price">0.84</td><td style="text-align: left"> </td><td> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pdd" style="text-align: right" title="Number Outstanding">150,000</td><td> </td> <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zXu13MmOa55g" style="text-align: right" title="Weighted Average Remaining Contractual Life">0.50</td><td> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pdd" style="text-align: right" title="Number Exercisable">150,000</td></tr> <tr style="background-color: White"> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_pdd" style="text-align: right" title="Exercise price">0.88</td><td style="text-align: left"> </td><td> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_pdd" style="text-align: right" title="Number Outstanding">150,000</td><td> </td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zFxhhY1kndT2" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.60</td><td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_pdd" style="text-align: right" title="Number Exercisable">150,000</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_pdd" style="text-align: right" title="Exercise price">0.93</td><td style="text-align: left"> </td><td> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Outstanding">50,000</td><td> </td> <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zcYlF7bcM0J3" style="text-align: right" title="Weighted Average Remaining Contractual Life">0.40</td><td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">50,000</td></tr> <tr style="background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231_zG89o3njE1Yb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Outstanding">3,625,000</td><td> </td> <td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zOSQwrat98H3" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.55</td><td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231_zphbXr3CUKGk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">3,625,000</td></tr> </table> Warrants During the year ended December 31, 2020, holders of warrants exercised warrants to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znmJVK0JS2g5" title="Warrants Exercised">7,855,062 shares of common stock at a price of $0.053 per share. In connection with the exercises, the Company received cash proceeds of $418,677 and issued 7,855,062 shares of common stock. During the year ended December 31, 2021, holders of warrants exercised warrants to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0O3Pic4DUri" title="Warrants Exercised">18,052,966 shares of common stock at a price of $0.053 per share. In connection with the exercises, the Company received cash proceeds of $962,223 and issued 18,052,966 shares of common stock. On August 30, 2021, a total of 68,723,698 of August 2016 warrants expired. During the year ended December 31, 2020, the Company issued 62,500 three-year immediately vested warrants to board members to purchase an aggregate of 62,500 shares of common stock with an exercise price of $0.2862 per share. The warrants had an aggregate grant date fair value of $1,372, which was recognized immediately as stock compensation within general and administrative expenses on the accompanying consolidated statements of operations. During the year ended December 31, 2021, the Company issued 25,000 three-year immediately vested warrants to an advisory board member to purchase an aggregate of 25,000 shares of common stock with exercise price of $0.28620 per share. The warrants had an aggregate grant date fair value of $488, which was recognized immediately within stock compensation in general and administrative expenses. In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: Schedule of Assumptions of Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td></tr> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td></tr> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Contractual terms (years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zwbJPyav6b96" title="Warrants outstanding, measurement input">92</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_ziyaP4ENrx2i" title="Warrants outstanding, measurement input">93%-<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zhtcOQYGdTIk" title="Warrants outstanding, measurement input">95</td><td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zEJVYIyJ4mKe" title="Warrants outstanding, measurement input">0.35</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z7xEWRrgG6H7" title="Warrants outstanding, measurement input">.011%-<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z1CMxFj739il" title="Warrants outstanding, measurement input">0.18</td><td style="text-align: left">%</td></tr> <tr style="background-color: White"> <td style="text-align: left">Expected dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zhOLMvDuPvBl" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zC6keOCXgiL2" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td></tr> </table> The following table summarizes warrant activity during the year ended December 31, 2021 and 2020: Summary of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted Average</td><td> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Outstanding and exercisable at January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231_za4vR2apWUHi" style="width: 15%; text-align: right" title="Warrants Outstanding and exercisable, beginning balance">126,109,532</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--WeightedAverageExercisePriceOutstanding_iS_c20200101__20201231_zsl2lNqzfAm3" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, beginning balance">0.29</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_zdVcKmSdeuNb" style="text-align: right" title="Warrants, Granted">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--WeightedAverageExercisePriceGranted_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.29</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231_zK1wdnLWbiq4" style="text-align: right" title="Warrants, Exercised">(7,855,062</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--WeightedAverageExercisePriceExercised_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Exercised">0.05</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200101__20201231_z3k56rAWU1L2" style="padding-bottom: 1.5pt; text-align: right" title="Warrants, Forfeited">(31,052,806</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceForfeited_c20200101__20201231_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.06</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Outstanding and exercisable at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zTwYSDh300oj" style="text-align: right" title="Warrants Outstanding and exercisable, beginning balance">87,264,164</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--WeightedAverageExercisePriceOutstanding_iS_c20210101__20211231_zgODtwDX3tXh" style="text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, beginning balance">0.02</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_pdd" style="text-align: right" title="Warrants, Granted">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--WeightedAverageExercisePriceGranted_c20210101__20211231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.29</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231_zwf14sUxRoYj" style="text-align: right" title="Warrants, Exercised">(18,052,966</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--WeightedAverageExercisePriceExercised_c20210101__20211231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Exercised">0.05</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20210101__20211231_zvODcB5oOabi" style="padding-bottom: 1.5pt; text-align: right" title="Warrants, Forfeited">(68,723,698</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceForfeited_c20210101__20211231_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">0.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding and exercisable at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zaNNuutfh1b4" style="padding-bottom: 2.5pt; text-align: right" title="Warrants Outstanding and exercisable, ending balance">512,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--WeightedAverageExercisePriceOutstanding_iE_c20210101__20211231_zfDvUr2i9lf1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, ending balance">0.92</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table> As of December 31, 2021, the intrinsic value of outstanding and exercisable warrants was $0. The following table summarizes information about warrants outstanding at December 31, 2021: Summary of Warrants Outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding Number of Warrant</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Life In Years</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercisable Number of Warrants</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 1%">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zxh1YqOwtTDe" style="text-align: right; width: 20%" title="Warrants outstanding, Exercise price">0.29</td><td style="text-align: left; width: 1%"> </td><td style="width: 5%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z50AyxTXagqk" style="text-align: right; width: 19%" title="Number of Warrant, Outstanding">125,000</td><td style="text-align: left; width: 1%"> </td><td style="width: 5%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zJPnfHi1ZCN5" style="text-align: right; width: 19%" title="Weighted Average Remaining Contractual Life, Warrants Exercisable">1.49</td><td style="text-align: left; width: 1%"> </td><td style="width: 5%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2c6rC7H84ed" style="text-align: right; width: 19%" title="Number of Warrants, Exercisable">125,000</td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zi1DFXcKTvX1" style="text-align: right" title="Warrants outstanding, Exercise price">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zn0FrqhnrQ22" style="text-align: right" title="Number Outstanding">18,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zBxSsRiDGzu8" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.39</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zFEjCpmLsLki" style="text-align: right" title="Number Exercisable">18,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zsP0OpzgcDq7" style="text-align: right" title="Warrants outstanding, Exercise price">1.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhqq6TmeP8l7" style="text-align: right" title="Number Outstanding">366,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmapsyiPrRee" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.39</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zUfiNwbsHkgk" style="text-align: right" title="Number Exercisable">366,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zrqilUDweJZg" style="padding-bottom: 1.5pt; text-align: right" title="Warrants outstanding, Exercise price">2.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zoABxrI6voSh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrant, Outstanding">3,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zYHOFuRq72li" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Remaining Contractual Life, Warrants Exercisable">2.39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zTTzuuU6udqk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercisable">3,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right" title="Weighted Average Exercise price"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number Outstanding"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Weighted Average Remaining Contractual Life"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number Exercisable"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise price"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zvz3UTazMebe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrant, Outstanding">512,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z3To343Mg0b3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Remaining Contractual Life, Warrants Exercisable">2.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231_zREwEZRwzcDj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable">512,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Holders of the outstanding warrants are not entitled to vote and the exercise prices of such warrants are subject to customary anti-dilution provisions.

20000000

P10Y

16437500

2425000

0.12

62880

100000

0.2862

1414

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsqCjTRxTU49" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Stock options granted during the year ended December 31, 2020 were valued using the Black Scholes Model, with the following assumptions used: Schedule of Stock Options Granted Valued Using Black Scholes Model <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 0.5in"> <tr style="background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Expected terms (years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2.50</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93</td><td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.23</td><td style="text-align: left">%</td></tr> <tr style="background-color: White"> <td style="text-align: left">Expected dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> </table>

P2Y6M

0.93

0.0023

0.0000

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zBZuk8hPCU34" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table summarizes option activity during the year ended December 31, 2021 and 2020: Summary of Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center">Weighted Average</td><td style="text-align: center; vertical-align: bottom"> </td> </tr> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Exercise Price</td><td style="text-align: center; vertical-align: bottom"> </td> </tr> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 68%">Outstanding and exercisable at January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20200101__20201231_z88MT9zognu" style="width: 12%; text-align: right" title="Number of Options Outstanding and exercisable, beginning balance">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zCwar8TqAi9i" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, beginning balance">0.88</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20201231_zLZRJdm0BCk8" style="text-align: right" title="Number of Options, Granted">2,525,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.20</td><td style="text-align: left"> </td> </tr> <tr style="background-color: White"> <td style="text-align: left; padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20200101__20201231_z8GZaG5oGyIf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(725,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">0.88</td><td style="text-align: left"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Outstanding and exercisable at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zWV0uGmodHAj" style="text-align: right" title="Number of Options Outstanding and exercisable, beginning balance">4,800,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zhvjVw2oEfue" style="text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, beginning balance">0.46</td><td style="text-align: left"> </td> </tr> <tr style="background-color: White"> <td style="text-align: left; padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20211231_zia3qgcme3gj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(1,175,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zaW4orEj6TK1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">0.89</td><td style="text-align: left"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Outstanding and exercisable at December 31, 2021</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_zLAbgTq6IM9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding and exercisable, ending balance">3,625,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zM52PvY69j7e" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, ending balance">0.32</td><td style="text-align: left"> </td> </tr> </table>

3000000

0.88

2525000

0.20

725000

0.88

4800000

0.46

1175000

0.89

3625000

0.32

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z2rT16Yljby9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table summarizes information about stock options outstanding at December 31, 2021: Summary of Stock Options Outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center">Options Outstanding</td><td> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">Options Exercisable</td></tr> <tr> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Exercise Price</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Outstanding Number of Options</td><td style="text-align: center; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted Average Remaining Life In Years</td><td style="text-align: center; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Exercisable Number of Options</td></tr> <tr> <td colspan="2"> </td><td> </td><td> </td> <td> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pdd" style="width: 16%; text-align: right" title="Exercise price">0.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pdd" style="width: 26%; text-align: right" title="Number Outstanding">2,425,000</td><td style="width: 2%"> </td> <td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOJfBV0aF8m1" style="width: 26%; text-align: right" title="Weighted Average Remaining Contractual Life">3.90</td><td style="width: 2%"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pdd" style="width: 26%; text-align: right" title="Number Exercisable">2,425,000</td></tr> <tr style="background-color: White"> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pdd" style="text-align: right" title="Exercise price">0.29</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pdd" style="text-align: right" title="Number Outstanding">100,000</td><td> </td> <td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zOEDvii4LaW3" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.90</td><td> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pdd" style="text-align: right" title="Number Exercisable">100,000</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pdd" style="text-align: right" title="Exercise price">0.67</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pdd" style="text-align: right" title="Number Outstanding">200,000</td><td> </td> <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zn4QtkV1Dc98" style="text-align: right" title="Weighted Average Remaining Contractual Life">1.60</td><td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pdd" style="text-align: right" title="Number Exercisable">200,000</td></tr> <tr style="background-color: White"> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pdd" style="text-align: right" title="Exercise price">0.75</td><td style="text-align: left"> </td><td> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pdd" style="text-align: right" title="Number Outstanding">550,000</td><td> </td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zwGac4LnAkf" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.90</td><td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pdd" style="text-align: right" title="Number Exercisable">550,000</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pdd" style="text-align: right" title="Exercise price">0.84</td><td style="text-align: left"> </td><td> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pdd" style="text-align: right" title="Number Outstanding">150,000</td><td> </td> <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zXu13MmOa55g" style="text-align: right" title="Weighted Average Remaining Contractual Life">0.50</td><td> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_pdd" style="text-align: right" title="Number Exercisable">150,000</td></tr> <tr style="background-color: White"> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_pdd" style="text-align: right" title="Exercise price">0.88</td><td style="text-align: left"> </td><td> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_pdd" style="text-align: right" title="Number Outstanding">150,000</td><td> </td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zFxhhY1kndT2" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.60</td><td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_pdd" style="text-align: right" title="Number Exercisable">150,000</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_pdd" style="text-align: right" title="Exercise price">0.93</td><td style="text-align: left"> </td><td> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Outstanding">50,000</td><td> </td> <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zcYlF7bcM0J3" style="text-align: right" title="Weighted Average Remaining Contractual Life">0.40</td><td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">50,000</td></tr> <tr style="background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231_zG89o3njE1Yb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Outstanding">3,625,000</td><td> </td> <td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zOSQwrat98H3" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.55</td><td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231_zphbXr3CUKGk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">3,625,000</td></tr> </table>

0.12

2425000

P3Y10M24D

2425000

0.29

100000

P3Y10M24D

100000

0.67

200000

P1Y7M6D

200000

0.75

550000

P3Y10M24D

550000

0.84

150000

P0Y6M

150000

0.88

150000

P2Y7M6D

150000

0.93

50000

P0Y4M24D

50000

3625000

P3Y6M18D

3625000

7855062

0.053

418677

7855062

18052966

0.053

962223

18052966

68723698

62500

0.2862

1372

25000

0.28620

488

In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: Schedule of Assumptions of Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td></tr> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td></tr> <tr> <td style="text-align: left; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Contractual terms (years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zwbJPyav6b96" title="Warrants outstanding, measurement input">92</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_ziyaP4ENrx2i" title="Warrants outstanding, measurement input">93%-<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zhtcOQYGdTIk" title="Warrants outstanding, measurement input">95</td><td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zEJVYIyJ4mKe" title="Warrants outstanding, measurement input">0.35</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z7xEWRrgG6H7" title="Warrants outstanding, measurement input">.011%-<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z1CMxFj739il" title="Warrants outstanding, measurement input">0.18</td><td style="text-align: left">%</td></tr> <tr style="background-color: White"> <td style="text-align: left">Expected dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zhOLMvDuPvBl" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zC6keOCXgiL2" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td></tr> </table>

P3Y

0.35

0.011

0.18

0.00

The following table summarizes warrant activity during the year ended December 31, 2021 and 2020: Summary of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted Average</td><td> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Outstanding and exercisable at January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231_za4vR2apWUHi" style="width: 15%; text-align: right" title="Warrants Outstanding and exercisable, beginning balance">126,109,532</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--WeightedAverageExercisePriceOutstanding_iS_c20200101__20201231_zsl2lNqzfAm3" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, beginning balance">0.29</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_zdVcKmSdeuNb" style="text-align: right" title="Warrants, Granted">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--WeightedAverageExercisePriceGranted_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.29</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231_zK1wdnLWbiq4" style="text-align: right" title="Warrants, Exercised">(7,855,062</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--WeightedAverageExercisePriceExercised_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Exercised">0.05</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200101__20201231_z3k56rAWU1L2" style="padding-bottom: 1.5pt; text-align: right" title="Warrants, Forfeited">(31,052,806</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceForfeited_c20200101__20201231_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.06</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Outstanding and exercisable at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zTwYSDh300oj" style="text-align: right" title="Warrants Outstanding and exercisable, beginning balance">87,264,164</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--WeightedAverageExercisePriceOutstanding_iS_c20210101__20211231_zgODtwDX3tXh" style="text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, beginning balance">0.02</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_pdd" style="text-align: right" title="Warrants, Granted">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--WeightedAverageExercisePriceGranted_c20210101__20211231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.29</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231_zwf14sUxRoYj" style="text-align: right" title="Warrants, Exercised">(18,052,966</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--WeightedAverageExercisePriceExercised_c20210101__20211231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Exercised">0.05</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20210101__20211231_zvODcB5oOabi" style="padding-bottom: 1.5pt; text-align: right" title="Warrants, Forfeited">(68,723,698</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceForfeited_c20210101__20211231_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">0.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding and exercisable at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zaNNuutfh1b4" style="padding-bottom: 2.5pt; text-align: right" title="Warrants Outstanding and exercisable, ending balance">512,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--WeightedAverageExercisePriceOutstanding_iE_c20210101__20211231_zfDvUr2i9lf1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding and exercisable, ending balance">0.92</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table>

126109532

0.29

62500

0.29

7855062

0.05

31052806

1.06

87264164

0.02

25000

0.29

18052966

0.05

68723698

0.05

512500

0.92 0 The following table summarizes information about warrants outstanding at December 31, 2021: Summary of Warrants Outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding Number of Warrant</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Life In Years</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercisable Number of Warrants</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 1%">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zxh1YqOwtTDe" style="text-align: right; width: 20%" title="Warrants outstanding, Exercise price">0.29</td><td style="text-align: left; width: 1%"> </td><td style="width: 5%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z50AyxTXagqk" style="text-align: right; width: 19%" title="Number of Warrant, Outstanding">125,000</td><td style="text-align: left; width: 1%"> </td><td style="width: 5%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zJPnfHi1ZCN5" style="text-align: right; width: 19%" title="Weighted Average Remaining Contractual Life, Warrants Exercisable">1.49</td><td style="text-align: left; width: 1%"> </td><td style="width: 5%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2c6rC7H84ed" style="text-align: right; width: 19%" title="Number of Warrants, Exercisable">125,000</td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zi1DFXcKTvX1" style="text-align: right" title="Warrants outstanding, Exercise price">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zn0FrqhnrQ22" style="text-align: right" title="Number Outstanding">18,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zBxSsRiDGzu8" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.39</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zFEjCpmLsLki" style="text-align: right" title="Number Exercisable">18,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zsP0OpzgcDq7" style="text-align: right" title="Warrants outstanding, Exercise price">1.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhqq6TmeP8l7" style="text-align: right" title="Number Outstanding">366,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmapsyiPrRee" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.39</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zUfiNwbsHkgk" style="text-align: right" title="Number Exercisable">366,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zrqilUDweJZg" style="padding-bottom: 1.5pt; text-align: right" title="Warrants outstanding, Exercise price">2.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zoABxrI6voSh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrant, Outstanding">3,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zYHOFuRq72li" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Remaining Contractual Life, Warrants Exercisable">2.39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zTTzuuU6udqk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercisable">3,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right" title="Weighted Average Exercise price"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number Outstanding"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Weighted Average Remaining Contractual Life"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number Exercisable"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise price"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zvz3UTazMebe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrant, Outstanding">512,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z3To343Mg0b3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Remaining Contractual Life, Warrants Exercisable">2.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231_zREwEZRwzcDj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable">512,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.29

125000

P1Y5M26D 125000

1.00

18000

P2Y4M20D 18000

1.12

366000

P2Y4M20D 366000

2.00

3500

P2Y4M20D 3500

512500

P2Y2M1D 512500

11. Income Taxes <p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zx27BftZfTT3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The domestic and foreign components of loss before income taxes from operations for the years ended December 31, 2021 and 2020 are as follows: Schedule of Domestic and Foreign Loss Before Income Taxes <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20210101_20211231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzbV9_zcGKUgHkmW35" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%">Domestic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,454,489</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(6,632,593</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzbV9_z1BIAuk7xus" style="background-color: White"> <td style="padding-left: 10pt">Foreign</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(85,053</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(44,994</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pp0p0_mtILFCOzbV9_zC5QVXXWXq4j" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Net Pre-Tax Loss</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,539,542</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,677,587</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z3maJ7rFel6k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The income tax provision (benefit) consists of the following: Summary of Income Tax Provision (Benefit) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Federal:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--CurrentFederalTaxExpenseBenefit_c20210101__20211231_pdp0" style="text-align: right" title="Federal: Current">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--CurrentFederalTaxExpenseBenefit_c20200101__20201231_pdp0" style="text-align: right" title="Federal: Current">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-left: 10pt">Deferred</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20210101__20211231_pp0p0" style="width: 16%; text-align: right" title="Federal: Deferred">295,524</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_pp0p0" style="width: 16%; text-align: right" title="Federal: Deferred">221,598</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">State and local:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20210101__20211231_pdp0" style="text-align: right" title="State and local: Current">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_pdp0" style="text-align: right" title="State and local: Current">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.14</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20210101__20211231_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="State and local: Deferred">72,262</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="State and local: Deferred">54,186</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">26.14</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_989_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20210101__20211231_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Current income tax expense (benefit)">367,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_986_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20200101__20201231_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Current income tax expense (benefit)">275,784</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pp0p0_di_c20210101__20211231_z5ZGGbZBnHw4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in valuation allowance">(367,786</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pp0p0_di_c20200101__20201231_zYcEN6VpOf1l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in valuation allowance">(275,784</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231_pdp0" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_pdp0" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCaLxIk3WVol" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The reconciliations between the statutory federal income tax rate and the Company’s effective tax rate are as follows: Schedule of Statutory Federal Income Tax Rate and Effective Tax Rate <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20210101__20211231_zaMznQScRFUi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20200101__20201231_zvSkn2YNeW1h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_uPure_zkvfuI2pbutl" style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Tax benefit at federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_zG6DyfbDlVZg" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">State income taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5.1</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5.1</td><td style="text-align: left">)%</td></tr> <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp_uPure_z7IUQNvEzpz4" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.9</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.7</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_zsXRUIrhGDH8" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7.2</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4.1</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationPriorYearTrueup_dp_uPure_zsTHfJ17VlVa" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Prior year true-up</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationExpirationOfStateNetOperatingLossCarryForwardsPercentage_dp_uPure_z8S7uf2IezWd" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Expiration of state net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationExpirationOfWarrantsAndOptions_dp_uPure_zSb9JAPNygH3" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Expiration of warrants and options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationConversionOfAccruedInterestToPreferredStock_dp_uPure_zFNtMHRnliMb" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Conversion of accrued interest to preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21.4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationMiscellaneous_dp_uPure_zFon0dACtiP2" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Miscellaneous</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_zg8RM3c5lnTe" style="background-color: White"> <td style="text-align: left">Effective income tax rate</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="text-align: left">%</td></tr> </table> The components of the Company’s deferred income taxes are summarized below: Schedule of Components of Deferred Income Taxes <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20211231_z9GPHOxsDnDe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20201231_z6grdfPbLa1d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zVqee3wIucsk" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz8lc_zwrHMjhCdo6k" style="background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">43,453,746</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">42,779,590</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pp0p0_maDTAGz8lc_z3WWOHw5p6q4" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">428,726</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0_maDTAGz8lc_zRcImso2VX8j" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">227,397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,296</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGz8lc_zRu5yFJhrzte" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development credit carryovers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,049,608</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,985,215</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_iI_pp0p0_maDTAGz8lc_zGY1iy9p8m0a" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Contribution carryovers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,062</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,062</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pp0p0_maDTAGz8lc_zYu3GhlQd1Oa" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accrued liabilities</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">505,038</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,503,190</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz8lc_maDTANzr5H_zvPrcSooYs6d" style="background-color: White"> <td style="text-align: left">Gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,432,623</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,801,079</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zczFCOHhMRM9" style="background-color: White"> <td style="text-align: left">Deferred Tax Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pp0p0_di_maDITLzLWw_z3rb29AIkRT5" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_pp0p0_di_maDITLzLWw_zmOPmTYfIQK5" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(82,179</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(82,839</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesOther_iNI_pp0p0_di_maDITLzLWw_ziVxlDNosEy7" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Other</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,604</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,603</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLzLWw_msDTANzr5H_zbPNfevVchZ7" style="background-color: White"> <td style="text-align: left">Gross deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(122,783</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(123,442</td><td style="text-align: left">)</td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzr5H_zXIuIt3aQ4Ba" style="background-color: White"> <td style="text-align: left">Valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47,309,840</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47,677,637</td><td style="text-align: left">)</td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzr5H_zKXZT7d7nTF3" style="background-color: White"> <td style="text-align: left">Deferred tax asset, net of valuation allowance</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pp0p0_c20210101__20211231_zg2SKc01Fod5" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">367,786</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">275,784</td><td style="text-align: left"> </td></tr> </table> A valuation allowance against deferred tax assets is required if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets may not be realized. The Company is in the early stages of development and realization of the deferred tax assets is not considered more likely than not. As a result, the Company has recorded a full valuation allowance for the net deferred tax asset. Since inception of the Company on January 17, 2002, the Company has generated federal, state, and Australian tax net operating losses of approximately $170 million, $150 million, and $139 thousand, respectively. Under the Tax Cuts and Jobs Act, federal net operating losses incurred after December 31, 2017 may be carried forward indefinitely. The tax loss carryforwards of the Company may be subject to limitation by Section 382 of the Internal Revenue Code with respect to the amount utilizable each year. This limitation could reduce the Company’s ability to utilize net operating loss carryforwards. Federal net operating losses (“NOLS”) totaling $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--BetweenTwoThousandAndTwentyTwoAndTwoThousandAndThirtySevenMember_z4MsxNVb1e58">151.4 million expire in various amounts between 2022 and 2037. Federal NOLS totaling $18.6 million do not expire. Schedule of Net Operating Loss <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr> <td style="text-align: center">Year</td><td> </td> <td style="text-align: center">Year of</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr> <td style="border-bottom: Black 1.5pt solid; text-align: center">Generated</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiration</td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: center">2002</td><td style="width: 2%"> </td> <td id="xdx_983_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndTwoMember_zQdzWK3LIt92" style="width: 32%; text-align: center" title="Year Expired">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndTwoMember_zFGgd35SVaV8" style="width: 30%; text-align: right" title="Amount">5,794,541</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2003</td><td> </td> <td id="xdx_98A_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndThreeMember_zN4Kmamctama" style="text-align: center" title="Year Expired">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndThreeMember_pp0p0" style="text-align: right" title="Amount">1,520,649</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2004</td><td> </td> <td id="xdx_985_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndFourMember" style="text-align: center" title="Year Expired">2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndFourMember_pp0p0" style="text-align: right" title="Amount">3,571,227</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2005</td><td> </td> <td id="xdx_989_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndFiveMember" style="text-align: center" title="Year Expired">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndFiveMember_pp0p0" style="text-align: right" title="Amount">5,530,815</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2006</td><td> </td> <td id="xdx_982_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSixMember" style="text-align: center" title="Year Expired">2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSixMember_pp0p0" style="text-align: right" title="Amount">7,192,407</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2007</td><td> </td> <td id="xdx_989_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSevenMember" style="text-align: center" title="Year Expired">2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSevenMember_pp0p0" style="text-align: right" title="Amount">10,218,952</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2008</td><td> </td> <td id="xdx_98A_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndEightMember_zJoDqBqZT272" style="text-align: center" title="Year Expired">2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndEightMember_pp0p0" style="text-align: right" title="Amount">7,017,372</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2009</td><td> </td> <td id="xdx_989_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndNineMember" style="text-align: center" title="Year Expired">2029</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndNineMember_pp0p0" style="text-align: right" title="Amount">9,573,948</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2010</td><td> </td> <td id="xdx_985_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTenMember" style="text-align: center" title="Year Expired">2030</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTenMember_pp0p0" style="text-align: right" title="Amount">10,344,298</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2011</td><td> </td> <td id="xdx_988_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandElevenMember" style="text-align: center" title="Year Expired">2031</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandElevenMember_pp0p0" style="text-align: right" title="Amount">11,225,047</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2012</td><td> </td> <td id="xdx_981_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTwelveMember" style="text-align: center" title="Year Expired">2032</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTwelveMember_pp0p0" style="text-align: right" title="Amount">11,193,882</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2013</td><td> </td> <td id="xdx_98D_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandThirteenMember" style="text-align: center" title="Year Expired">2033</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandThirteenMember_pp0p0" style="text-align: right" title="Amount">10,273,181</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2014</td><td> </td> <td id="xdx_980_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandFourteenMember" style="text-align: center" title="Year Expired">2034</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandFourteenMember_pp0p0" style="text-align: right" title="Amount">9,075,738</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2015</td><td> </td> <td id="xdx_980_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandFifteenMember" style="text-align: center" title="Year Expired">2035</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandFifteenMember_pp0p0" style="text-align: right" title="Amount">17,455,417</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2016</td><td> </td> <td id="xdx_981_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandSixteenMember" style="text-align: center" title="Year Expired">2036</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandSixteenMember_pp0p0" style="text-align: right" title="Amount">19,710,699</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2017</td><td> </td> <td id="xdx_989_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenMember" style="text-align: center" title="Year Expired">2037</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenMember_pp0p0" style="text-align: right" title="Amount">11,703,175</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2018</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandEighteenMember_zB6AZOnzZBN7" style="text-align: right" title="Amount">6,255,067</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2019</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandNineteenMember_pp0p0" style="text-align: right" title="Amount">4,085,063</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2020</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyMember_zAuacKTgc8ma" style="text-align: right" title="Amount">4,167,397</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2021</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneMember_ztQX0U0IcfQ2" style="border-bottom: Black 1.5pt solid; text-align: right">4,166,084</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">Total NOLS</td><td> </td> <td> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember_zZm35SjMJCU2" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount">170,074,959</td><td style="text-align: left"> </td></tr> </table> State NOLS totaling $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--BetweenTwoThousandTwentyTwoAndTwoThousandThirtySixMember_zMX0A6QvCgC6" title="Tax net operating losses">150 million expire in various years between 2022 and 2036. <div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr> <td style="text-align: center">Year</td><td> </td> <td style="text-align: center">Year of</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr> <td style="border-bottom: Black 1.5pt solid; text-align: center">Generated</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiration</td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: center">2007</td><td style="width: 2%"> </td> <td id="xdx_98C_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSevenMember_z8MrgPG0CnK3" style="width: 32%; text-align: center" title="Year Expired">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSevenMember_zYUKY29wmsua" style="width: 30%; text-align: right" title="Amount">10,318,963</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2008</td><td> </td> <td id="xdx_984_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndEightMember_zxMuhSVujFC2" style="text-align: center" title="Year Expired">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndEightMember_pp0p0" style="text-align: right" title="Amount">7,106,425</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2009</td><td> </td> <td id="xdx_986_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndNineMember" style="text-align: center" title="Year Expired">2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndNineMember_zsRaK5GK9Fk2" style="text-align: right" title="Amount">9,680,770</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2010</td><td> </td> <td id="xdx_986_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTenMember" style="text-align: center" title="Year Expired">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTenMember_pp0p0" style="text-align: right" title="Amount">10,440,651</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2011</td><td> </td> <td id="xdx_98B_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandElevenMember" style="text-align: center" title="Year Expired">2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandElevenMember_pp0p0" style="text-align: right" title="Amount">11,362,120</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2012</td><td> </td> <td id="xdx_982_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwelveMember" style="text-align: center" title="Year Expired">2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwelveMember_pp0p0" style="text-align: right" title="Amount">11,311,394</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2013</td><td> </td> <td id="xdx_98A_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandThirteenMember" style="text-align: center" title="Year Expired">2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandThirteenMember_pp0p0" style="text-align: right" title="Amount">10,381,763</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2014</td><td> </td> <td id="xdx_987_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandFourteenMember" style="text-align: center" title="Year Expired">2029</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandFourteenMember_pp0p0" style="text-align: right" title="Amount">9,278,510</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2015</td><td> </td> <td id="xdx_980_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandFifteenMember" style="text-align: center" title="Year Expired">2030</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandFifteenMember_pp0p0" style="text-align: right" title="Amount">18,547,287</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2016</td><td> </td> <td id="xdx_981_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandSixteenMember" style="text-align: center" title="Year Expired">2031</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandSixteenMember_pp0p0" style="text-align: right" title="Amount">20,166,661</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2017</td><td> </td> <td id="xdx_986_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenMember" style="text-align: center" title="Year Expired">2032</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenMember_pp0p0" style="text-align: right" title="Amount">12,131,850</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2018</td><td> </td> <td id="xdx_982_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandEighteenMember" style="text-align: center" title="Year Expired">2033</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandEighteenMember_pp0p0" style="text-align: right" title="Amount">6,455,113</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2019</td><td> </td> <td id="xdx_986_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandNineteenMember" style="text-align: center" title="Year Expired">2034</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandNineteenMember_pp0p0" style="text-align: right" title="Amount">4,211,210</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2020</td><td> </td> <td id="xdx_985_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyMember" style="text-align: center" title="Year Expired">2035</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyMember_z5stNAStNoEh" style="text-align: right" title="Amount">4,234,755</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2021</td><td> </td> <td id="xdx_98F_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneMember_zmWNXgzINUC2" style="text-align: center" title="Year Expired">2036</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneMember_zeQuAMyx14j2" style="border-bottom: Black 1.5pt solid; text-align: right">4,166,084</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">Total NOLS</td><td> </td> <td> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zSvKrwSXGcMk" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount">149,793,556</td><td style="text-align: left"> </td></tr> </table> </div> Australia NOLS totaling $138,540 do not expire. <div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Generated</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year of Expiration</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount </td><td style="font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2017</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenMember_zMoOcXZ8v4p7" style="text-align: right" title="Amount">861</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="width: 32%; text-align: center">2018</td><td style="width: 2%"> </td> <td style="width: 32%; text-align: center">N/A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember__us-gaap--AwardDateAxis__custom--TwoThousandEighteenMember_zsue0OvB5VY2" style="width: 30%; text-align: right" title="Amount">54,101</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2019</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember__us-gaap--AwardDateAxis__custom--TwoThousandNineteenMember_zOCeZKReVS0e" style="text-align: right" title="Amount">13,843</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2020</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyMember_zqy8uDBlS0of" style="text-align: right" title="Amount">13,384</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2021</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneMember_zj9qARqCM5ne" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amount">56,351</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">Total NOLS</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember_zeX2IRdqohg9" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount">138,540</td><td style="text-align: left"> </td></tr> </table> </div> The Company has determined that there are no uncertain tax positions as of December 31, 2021 or 2020. The Company files income tax returns in the U.S. federal jurisdiction and the state of Tennessee. The Company intends to permanently reinvest earnings in its foreign subsidiary. To date, the Company’s operations conducted by its Australian subsidiary consist primarily of research and development activities. As of December 31, 2021, there were no accumulated earnings and profits in the Company’s foreign subsidiary. At current tax rates, no additional Federal income taxes (net of available tax credits) would be payable if such earnings were to be repatriated.

<p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zx27BftZfTT3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The domestic and foreign components of loss before income taxes from operations for the years ended December 31, 2021 and 2020 are as follows: Schedule of Domestic and Foreign Loss Before Income Taxes <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20210101_20211231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzbV9_zcGKUgHkmW35" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%">Domestic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,454,489</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(6,632,593</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzbV9_z1BIAuk7xus" style="background-color: White"> <td style="padding-left: 10pt">Foreign</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(85,053</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(44,994</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pp0p0_mtILFCOzbV9_zC5QVXXWXq4j" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Net Pre-Tax Loss</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,539,542</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,677,587</td><td style="text-align: left">)</td></tr> </table>

-5454489

-6632593

-85053

-44994

-5539542

-6677587

<p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z3maJ7rFel6k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The income tax provision (benefit) consists of the following: Summary of Income Tax Provision (Benefit) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Federal:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--CurrentFederalTaxExpenseBenefit_c20210101__20211231_pdp0" style="text-align: right" title="Federal: Current">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--CurrentFederalTaxExpenseBenefit_c20200101__20201231_pdp0" style="text-align: right" title="Federal: Current">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-left: 10pt">Deferred</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20210101__20211231_pp0p0" style="width: 16%; text-align: right" title="Federal: Deferred">295,524</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_pp0p0" style="width: 16%; text-align: right" title="Federal: Deferred">221,598</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">State and local:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20210101__20211231_pdp0" style="text-align: right" title="State and local: Current">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_pdp0" style="text-align: right" title="State and local: Current">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.14</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20210101__20211231_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="State and local: Deferred">72,262</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="State and local: Deferred">54,186</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">26.14</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_989_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20210101__20211231_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Current income tax expense (benefit)">367,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_986_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20200101__20201231_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Current income tax expense (benefit)">275,784</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pp0p0_di_c20210101__20211231_z5ZGGbZBnHw4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in valuation allowance">(367,786</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pp0p0_di_c20200101__20201231_zYcEN6VpOf1l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in valuation allowance">(275,784</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231_pdp0" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_pdp0" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.2100

295524

221598

0.0514 0.0514

72262

54186

0.2614 0.2614

367786

275784

367786

275784

<p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCaLxIk3WVol" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The reconciliations between the statutory federal income tax rate and the Company’s effective tax rate are as follows: Schedule of Statutory Federal Income Tax Rate and Effective Tax Rate <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20210101__20211231_zaMznQScRFUi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20200101__20201231_zvSkn2YNeW1h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_uPure_zkvfuI2pbutl" style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Tax benefit at federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_zG6DyfbDlVZg" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">State income taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5.1</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5.1</td><td style="text-align: left">)%</td></tr> <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp_uPure_z7IUQNvEzpz4" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.9</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.7</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_zsXRUIrhGDH8" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7.2</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4.1</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationPriorYearTrueup_dp_uPure_zsTHfJ17VlVa" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Prior year true-up</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationExpirationOfStateNetOperatingLossCarryForwardsPercentage_dp_uPure_z8S7uf2IezWd" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Expiration of state net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationExpirationOfWarrantsAndOptions_dp_uPure_zSb9JAPNygH3" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Expiration of warrants and options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationConversionOfAccruedInterestToPreferredStock_dp_uPure_zFNtMHRnliMb" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Conversion of accrued interest to preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21.4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationMiscellaneous_dp_uPure_zFon0dACtiP2" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Miscellaneous</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_zg8RM3c5lnTe" style="background-color: White"> <td style="text-align: left">Effective income tax rate</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="text-align: left">%</td></tr> </table>

0.210

-0.051

-0.009 -0.007

-0.072

-0.041

0.024 0.231 0.068 0.045 0.036 0.035 0.214 0.000 0.000 0.000

0.000

The components of the Company’s deferred income taxes are summarized below: Schedule of Components of Deferred Income Taxes <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20211231_z9GPHOxsDnDe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20201231_z6grdfPbLa1d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zVqee3wIucsk" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz8lc_zwrHMjhCdo6k" style="background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">43,453,746</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">42,779,590</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pp0p0_maDTAGz8lc_z3WWOHw5p6q4" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">428,726</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0_maDTAGz8lc_zRcImso2VX8j" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">227,397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,296</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGz8lc_zRu5yFJhrzte" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development credit carryovers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,049,608</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,985,215</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_iI_pp0p0_maDTAGz8lc_zGY1iy9p8m0a" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Contribution carryovers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,062</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,062</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pp0p0_maDTAGz8lc_zYu3GhlQd1Oa" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accrued liabilities</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">505,038</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,503,190</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz8lc_maDTANzr5H_zvPrcSooYs6d" style="background-color: White"> <td style="text-align: left">Gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,432,623</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,801,079</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zczFCOHhMRM9" style="background-color: White"> <td style="text-align: left">Deferred Tax Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pp0p0_di_maDITLzLWw_z3rb29AIkRT5" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_pp0p0_di_maDITLzLWw_zmOPmTYfIQK5" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(82,179</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(82,839</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesOther_iNI_pp0p0_di_maDITLzLWw_ziVxlDNosEy7" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Other</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,604</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,603</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLzLWw_msDTANzr5H_zbPNfevVchZ7" style="background-color: White"> <td style="text-align: left">Gross deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(122,783</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(123,442</td><td style="text-align: left">)</td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzr5H_zXIuIt3aQ4Ba" style="background-color: White"> <td style="text-align: left">Valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47,309,840</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47,677,637</td><td style="text-align: left">)</td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzr5H_zKXZT7d7nTF3" style="background-color: White"> <td style="text-align: left">Deferred tax asset, net of valuation allowance</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pp0p0_c20210101__20211231_zg2SKc01Fod5" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">367,786</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">275,784</td><td style="text-align: left"> </td></tr> </table>

43453746

42779590

186772

428726

227397

94296

3049608

2985215

10062

505038

1503190

47432623

47801079

82179

82839

40604

40603

122783

123442

47309840

47677637

367786

275784

170000000

150000000

139000

151400000

18600000

Schedule of Net Operating Loss <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr> <td style="text-align: center">Year</td><td> </td> <td style="text-align: center">Year of</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr> <td style="border-bottom: Black 1.5pt solid; text-align: center">Generated</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiration</td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: center">2002</td><td style="width: 2%"> </td> <td id="xdx_983_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndTwoMember_zQdzWK3LIt92" style="width: 32%; text-align: center" title="Year Expired">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndTwoMember_zFGgd35SVaV8" style="width: 30%; text-align: right" title="Amount">5,794,541</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2003</td><td> </td> <td id="xdx_98A_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndThreeMember_zN4Kmamctama" style="text-align: center" title="Year Expired">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndThreeMember_pp0p0" style="text-align: right" title="Amount">1,520,649</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2004</td><td> </td> <td id="xdx_985_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndFourMember" style="text-align: center" title="Year Expired">2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndFourMember_pp0p0" style="text-align: right" title="Amount">3,571,227</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2005</td><td> </td> <td id="xdx_989_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndFiveMember" style="text-align: center" title="Year Expired">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndFiveMember_pp0p0" style="text-align: right" title="Amount">5,530,815</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2006</td><td> </td> <td id="xdx_982_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSixMember" style="text-align: center" title="Year Expired">2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSixMember_pp0p0" style="text-align: right" title="Amount">7,192,407</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2007</td><td> </td> <td id="xdx_989_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSevenMember" style="text-align: center" title="Year Expired">2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSevenMember_pp0p0" style="text-align: right" title="Amount">10,218,952</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2008</td><td> </td> <td id="xdx_98A_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndEightMember_zJoDqBqZT272" style="text-align: center" title="Year Expired">2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndEightMember_pp0p0" style="text-align: right" title="Amount">7,017,372</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2009</td><td> </td> <td id="xdx_989_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndNineMember" style="text-align: center" title="Year Expired">2029</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandAndNineMember_pp0p0" style="text-align: right" title="Amount">9,573,948</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2010</td><td> </td> <td id="xdx_985_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTenMember" style="text-align: center" title="Year Expired">2030</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTenMember_pp0p0" style="text-align: right" title="Amount">10,344,298</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2011</td><td> </td> <td id="xdx_988_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandElevenMember" style="text-align: center" title="Year Expired">2031</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandElevenMember_pp0p0" style="text-align: right" title="Amount">11,225,047</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2012</td><td> </td> <td id="xdx_981_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTwelveMember" style="text-align: center" title="Year Expired">2032</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTwelveMember_pp0p0" style="text-align: right" title="Amount">11,193,882</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2013</td><td> </td> <td id="xdx_98D_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandThirteenMember" style="text-align: center" title="Year Expired">2033</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandThirteenMember_pp0p0" style="text-align: right" title="Amount">10,273,181</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2014</td><td> </td> <td id="xdx_980_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandFourteenMember" style="text-align: center" title="Year Expired">2034</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandFourteenMember_pp0p0" style="text-align: right" title="Amount">9,075,738</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2015</td><td> </td> <td id="xdx_980_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandFifteenMember" style="text-align: center" title="Year Expired">2035</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandFifteenMember_pp0p0" style="text-align: right" title="Amount">17,455,417</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2016</td><td> </td> <td id="xdx_981_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandSixteenMember" style="text-align: center" title="Year Expired">2036</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandSixteenMember_pp0p0" style="text-align: right" title="Amount">19,710,699</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2017</td><td> </td> <td id="xdx_989_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenMember" style="text-align: center" title="Year Expired">2037</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenMember_pp0p0" style="text-align: right" title="Amount">11,703,175</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2018</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandEighteenMember_zB6AZOnzZBN7" style="text-align: right" title="Amount">6,255,067</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2019</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandNineteenMember_pp0p0" style="text-align: right" title="Amount">4,085,063</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2020</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyMember_zAuacKTgc8ma" style="text-align: right" title="Amount">4,167,397</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2021</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneMember_ztQX0U0IcfQ2" style="border-bottom: Black 1.5pt solid; text-align: right">4,166,084</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">Total NOLS</td><td> </td> <td> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalCountryMember_zZm35SjMJCU2" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount">170,074,959</td><td style="text-align: left"> </td></tr> </table> State NOLS totaling $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--BetweenTwoThousandTwentyTwoAndTwoThousandThirtySixMember_zMX0A6QvCgC6" title="Tax net operating losses">150 million expire in various years between 2022 and 2036. <div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr> <td style="text-align: center">Year</td><td> </td> <td style="text-align: center">Year of</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr> <td style="border-bottom: Black 1.5pt solid; text-align: center">Generated</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiration</td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: center">2007</td><td style="width: 2%"> </td> <td id="xdx_98C_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSevenMember_z8MrgPG0CnK3" style="width: 32%; text-align: center" title="Year Expired">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndSevenMember_zYUKY29wmsua" style="width: 30%; text-align: right" title="Amount">10,318,963</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2008</td><td> </td> <td id="xdx_984_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndEightMember_zxMuhSVujFC2" style="text-align: center" title="Year Expired">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndEightMember_pp0p0" style="text-align: right" title="Amount">7,106,425</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2009</td><td> </td> <td id="xdx_986_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndNineMember" style="text-align: center" title="Year Expired">2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandAndNineMember_zsRaK5GK9Fk2" style="text-align: right" title="Amount">9,680,770</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2010</td><td> </td> <td id="xdx_986_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTenMember" style="text-align: center" title="Year Expired">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTenMember_pp0p0" style="text-align: right" title="Amount">10,440,651</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2011</td><td> </td> <td id="xdx_98B_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandElevenMember" style="text-align: center" title="Year Expired">2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandElevenMember_pp0p0" style="text-align: right" title="Amount">11,362,120</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2012</td><td> </td> <td id="xdx_982_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwelveMember" style="text-align: center" title="Year Expired">2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwelveMember_pp0p0" style="text-align: right" title="Amount">11,311,394</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2013</td><td> </td> <td id="xdx_98A_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandThirteenMember" style="text-align: center" title="Year Expired">2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandThirteenMember_pp0p0" style="text-align: right" title="Amount">10,381,763</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2014</td><td> </td> <td id="xdx_987_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandFourteenMember" style="text-align: center" title="Year Expired">2029</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandFourteenMember_pp0p0" style="text-align: right" title="Amount">9,278,510</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2015</td><td> </td> <td id="xdx_980_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandFifteenMember" style="text-align: center" title="Year Expired">2030</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandFifteenMember_pp0p0" style="text-align: right" title="Amount">18,547,287</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2016</td><td> </td> <td id="xdx_981_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandSixteenMember" style="text-align: center" title="Year Expired">2031</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandSixteenMember_pp0p0" style="text-align: right" title="Amount">20,166,661</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2017</td><td> </td> <td id="xdx_986_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenMember" style="text-align: center" title="Year Expired">2032</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenMember_pp0p0" style="text-align: right" title="Amount">12,131,850</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2018</td><td> </td> <td id="xdx_982_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandEighteenMember" style="text-align: center" title="Year Expired">2033</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandEighteenMember_pp0p0" style="text-align: right" title="Amount">6,455,113</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2019</td><td> </td> <td id="xdx_986_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandNineteenMember" style="text-align: center" title="Year Expired">2034</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLossCarryforwards_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandNineteenMember_pp0p0" style="text-align: right" title="Amount">4,211,210</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2020</td><td> </td> <td id="xdx_985_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyMember" style="text-align: center" title="Year Expired">2035</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyMember_z5stNAStNoEh" style="text-align: right" title="Amount">4,234,755</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2021</td><td> </td> <td id="xdx_98F_ecustom--YearExpired_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneMember_zmWNXgzINUC2" style="text-align: center" title="Year Expired">2036</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneMember_zeQuAMyx14j2" style="border-bottom: Black 1.5pt solid; text-align: right">4,166,084</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">Total NOLS</td><td> </td> <td> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zSvKrwSXGcMk" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount">149,793,556</td><td style="text-align: left"> </td></tr> </table> </div> Australia NOLS totaling $138,540 do not expire. <div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Generated</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year of Expiration</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount </td><td style="font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2017</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenMember_zMoOcXZ8v4p7" style="text-align: right" title="Amount">861</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="width: 32%; text-align: center">2018</td><td style="width: 2%"> </td> <td style="width: 32%; text-align: center">N/A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember__us-gaap--AwardDateAxis__custom--TwoThousandEighteenMember_zsue0OvB5VY2" style="width: 30%; text-align: right" title="Amount">54,101</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2019</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember__us-gaap--AwardDateAxis__custom--TwoThousandNineteenMember_zOCeZKReVS0e" style="text-align: right" title="Amount">13,843</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">2020</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyMember_zqy8uDBlS0of" style="text-align: right" title="Amount">13,384</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: center">2021</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneMember_zj9qARqCM5ne" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amount">56,351</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: center">Total NOLS</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__custom--AustralianTaxAuthorityMember_zeX2IRdqohg9" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount">138,540</td><td style="text-align: left"> </td></tr> </table> </div> 2022

5794541

2023

1520649

2024

3571227

2025

5530815

2026

7192407

2027

10218952

2028

7017372

2029

9573948

2030

10344298

2031

11225047

2032

11193882

2033

10273181

2034

9075738

2035

17455417

2036

19710699

2037

11703175

6255067

4085063

4167397

4166084

170074959

150000000

2022

10318963

2023

7106425

2024

9680770

2025

10440651

2026

11362120

2027

11311394

2028

10381763

2029

9278510

2030

18547287

2031

20166661

2032

12131850

2033

6455113

2034

4211210

2035

4234755

2036

4166084

149793556

138540

861

54101

13843

13384

56351

138540

12. Leases Leases The Company currently leases 4,500 square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five years ending on June 30, 2022. Payments are approximately $6,100 per month. On August 13, 2021, the Company negotiated a reduced rent from July 1, 2021 through December 31, 2021 in the amount of $6,100 per month. Total expense for operating leases for the year ended December 31, 2021 was $86,545, of which, $57,697 was included within research and development and $28,848 was included within general and administrative expenses on the consolidated statements of operations. Total expense for operating leases for the year ended December 31, 2020 was $90,821, of which, $60,547 was included within research and development and $<span id="xdx_90C_eus-gaap--OperatingLeaseExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zmeeekZzCwG7" title="Operating lease expense">30,274 was included within general and administrative expenses on the consolidated statements of operations. As of December 31, 2021, the Company had no leases that were classified as a financing lease. As of December 31, 2021, the Company did not have additional operating and financing leases that have not yet commenced. A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For The Years Ended</td><td style="font-weight: bold"> </td></tr> <tr> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Operating cash flows used in operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeasePayments_pp0p0_c20210101__20211231_zUaYVUebY038" style="width: 16%; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases">82,678</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeasePayments_c20200101__20201231_pp0p0" style="width: 16%; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases">91,605</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210101__20211231_pp0p0" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligations: Operating leases">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20200101__20201231_pdp0" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligations: Operating leases">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.50 Years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.50 Years</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="font-weight: bold">Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr> </table> Future minimum payments under non-cancellable lease as of December 31, 2021 were as follows: Schedule of Future Minimum Payments Under Non-cancellable Lease <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20211231_z9BQzFBSFy6f" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzwz3_zT2mloo09nq4" style="background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right">46,687</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzwz3_zT02s1iIafFk" style="background-color: White"> <td style="text-align: left; padding-left: 10pt">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,687</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zdiALLijMF4e" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 20pt">Less: amount representing imputed interest</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,070</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="background-color: White"> <td>Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">45,617</td><td style="text-align: left"> </td></tr> </table>

4500

P5Y

2022-06-30

6100

86545

57697

28848

90821

60547

30274

A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For The Years Ended</td><td style="font-weight: bold"> </td></tr> <tr> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Operating cash flows used in operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeasePayments_pp0p0_c20210101__20211231_zUaYVUebY038" style="width: 16%; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases">82,678</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeasePayments_c20200101__20201231_pp0p0" style="width: 16%; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases">91,605</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210101__20211231_pp0p0" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligations: Operating leases">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20200101__20201231_pdp0" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligations: Operating leases">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.50 Years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.50 Years</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="font-weight: bold">Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr> </table>

82678

91605

P0Y6M

P1Y6M

0.080

Future minimum payments under non-cancellable lease as of December 31, 2021 were as follows: Schedule of Future Minimum Payments Under Non-cancellable Lease <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20211231_z9BQzFBSFy6f" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzwz3_zT2mloo09nq4" style="background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right">46,687</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzwz3_zT02s1iIafFk" style="background-color: White"> <td style="text-align: left; padding-left: 10pt">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,687</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zdiALLijMF4e" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 20pt">Less: amount representing imputed interest</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,070</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="background-color: White"> <td>Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">45,617</td><td style="text-align: left"> </td></tr> </table>

46687

1070

45617

<p id="xdx_809_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zSYGk6OmU0f3" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">13. 401(K) Profit Sharing Plan The Company maintains a retirement plan under Section 401(k) of the Internal Revenue Code, which covers all eligible employees. All employees with U.S. source income are eligible to participate in the plan immediately upon employment. There was no contribution made by the Company in 2021 or 2020.

14. Grants On October 25, 2021, the Company received a grant award of $2,500,000 from the State of Tennessee for the study of animal cancers and dermatological disorders for the period October 15, 2021 to June 30, 2022. As of December 31, 2021, the grant award is recorded as unearned grant revenue liability on the accompanying consolidated balance sheets. 2500000

15. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising in the ordinary course of business or which may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

16. Subsequent Events The Company has evaluated events that have occurred after the balance sheet date and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. On February 23, 2022, the Company negotiated a continued reduced rent from January 1, 2022 through June 30, 2022 in the amount of $6,100 per month.

6100